<SEC-DOCUMENT>0001104659-25-116507.txt : 20251128
<SEC-HEADER>0001104659-25-116507.hdr.sgml : 20251128
<ACCEPTANCE-DATETIME>20251126174835
ACCESSION NUMBER:		0001104659-25-116507
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20251128
DATE AS OF CHANGE:		20251126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alto Neuroscience, Inc.
		CENTRAL INDEX KEY:			0001999480
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				834210124
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-291834
		FILM NUMBER:		251531741

	BUSINESS ADDRESS:	
		STREET 1:		650 CASTRO STREET, SUITE 450
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94041
		BUSINESS PHONE:		773-255-5012

	MAIL ADDRESS:	
		STREET 1:		650 CASTRO STREET, SUITE 450
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94041
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>tm2531771-1_s3.htm
<DESCRIPTION>S-3
<TEXT>
<html>
  <head>
    <title>tm2531771-1_s3 - none - 3.784818s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">As filed with the Securities and Exchange Commission on November&#160;26, 2025</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:1pt; text-align:right; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>&#8203;</div>
        <div style="margin-top:1pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1.5pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:14.5pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">UNITED STATES </font>
          <br >
          <font style="letter-spacing:-0.28pt;">SECURITIES AND EXCHANGE COMMISSION</font>
          <br >
          <font style="font-size:9pt;letter-spacing:-0.18pt;">Washington, D.C. 20549</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541.31pt; line-height:14.5pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">FORM S-3 </font>
        </div>
        <div style="margin-top:0.5pt; text-align:center; width:541.31pt; line-height:9pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">REGISTRATION STATEMENT </font>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541.31pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">UNDER </font>
          <br >
          <font style="letter-spacing:-0.18pt;">THE SECURITIES ACT OF 1933</font><font style="font-style:normal;font-weight:normal;font-size:14pt;">&#8203;<font style="letter-spacing:0.28pt;"> </font></font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541.31pt; line-height:9.5pt;font-size:14pt;">
          <font style="font-weight:bold;letter-spacing:-0.28pt;">ALTO NEUROSCIENCE, INC. </font>
          <br >
          <font style="font-size:8pt;letter-spacing:0.16pt;">(Exact name of registrant as specified in its charter)</font><font style="letter-spacing:0.28pt;"> </font>
        </div>
        <table style="width:541.31pt;height:29pt;margin-top:8.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.18pt;">Delaware </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.65pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.18pt;">83-4210124 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0.633pt 0pt 0.5pt 0pt; width:264.66pt;">
              <div style="text-align:center; line-height:9pt;">
                <font style="letter-spacing:0.16pt;">(State or other jurisdiction of</font>
                <br >
                <font style="letter-spacing:0.16pt;">incorporation or organization)</font><font style="font-size:9pt;">&#8203;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.633pt 0pt 0.5pt 0pt; width:264.65pt;">
              <div style="text-align:center; line-height:9pt;">
                <font style="letter-spacing:0.16pt;">(I.R.S. Employer</font>
                <br >
                <font style="letter-spacing:0.16pt;">Identification Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.5pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">650 Castro St, Suite 450 </font>
          <br >
          <font style="letter-spacing:-0.18pt;">Mountain View, CA 94041 </font>
          <br >
          <font style="letter-spacing:-0.18pt;">(650) 200-0412</font>
        </div>
        <div style="margin-top:0.5pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Address, including zip code, and telephone number, including area code of registrant&#8217;s principal executive offices)</font><font style="font-size:9pt;">&#8203;<font style="letter-spacing:0.18pt;"> </font></font>
        </div>
        <div style="margin-top:3.5pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Amit Etkin, M.D., Ph.D.</font>
          <br >
          <font style="letter-spacing:-0.18pt;">President and Chief Executive Officer </font>
          <br >
          <font style="letter-spacing:-0.18pt;">Alto Neuroscience, Inc. </font>
          <br >
          <font style="letter-spacing:-0.18pt;">650 Castro St, Suite 450 </font>
          <br >
          <font style="letter-spacing:-0.18pt;">Mountain View, CA 94041 </font>
          <br >
          <font style="letter-spacing:-0.18pt;">(650) 200-0412</font>
        </div>
        <div style="margin-top:0.5pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font><font style="font-size:9pt;">&#8203;<font style="letter-spacing:0.18pt;"> </font></font>
        </div>
        <div style="margin-top:3.5pt; text-align:center; width:541.31pt; line-height:9.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Copies to:</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <table style="width:541.31pt;margin-top:6.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
          <tr style="line-height:9.47pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:264.66pt;">
              <div style="text-align:center; line-height:9.48pt;">
                <font style="letter-spacing:-0.18pt;">Divakar Gupta</font>
                <br >
                <font style="letter-spacing:-0.18pt;">Courtney M.W. Tygesson</font>
                <br >
                <font style="letter-spacing:-0.18pt;">Madison A. Jones</font>
                <br >
                <font style="letter-spacing:-0.18pt;">Cooley LLP</font>
                <br >
                <font style="letter-spacing:-0.18pt;">110 N. Wacker Drive, Suite 4200</font>
                <br >
                <font style="letter-spacing:-0.18pt;">Chicago, IL 60606</font>
                <br >
                <font style="letter-spacing:-0.18pt;">(312) 881-6500</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:264.65pt;">
              <div style="text-align:center; line-height:9.48pt;">
                <font style="letter-spacing:-0.18pt;">Nicholas Smith</font>
                <br >
                <font style="letter-spacing:-0.18pt;">Chief Financial Officer</font>
                <br >
                <font style="letter-spacing:-0.18pt;">Alto Neuroscience, Inc.</font>
                <br >
                <font style="letter-spacing:-0.18pt;">650 Castro Street, Suite 450</font>
                <br >
                <font style="letter-spacing:-0.18pt;">Mountain View, CA 94041</font>
                <br >
                <font style="letter-spacing:-0.18pt;">(650) 200-0412</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.5pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">From time to time after the effective date of this Registration Statement </font>
          <br >
          <font style="letter-spacing:-0.18pt;">(Approximate date of commencement of proposed sale to the public)</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.18pt;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.18pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&#160;&#9746; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.18pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.18pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.18pt;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.18pt;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.18pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </font>
        </div>
        <table style="width:501.31pt;height:29.5599999999999pt;margin-left:20pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
          <tr style="line-height:8.97000000000003pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:180pt;white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Large accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:180pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.18pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.65pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:216pt;white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:216pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.18pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.53pt 0pt 0.5pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:180pt;white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Non-accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:180pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.18pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.53pt 0pt 0.5pt 0pt; width:244.65pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:216pt;white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Smaller reporting company</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:216pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.18pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.66pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.53pt 0pt 0.5pt 0pt; width:244.65pt;white-space:normal;">
              <div style=" float:left; line-height:9pt; text-align:left; width:216pt;white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Emerging growth company</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:216pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.18pt;">&#9746;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:11.5pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.18pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3.5pt; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</font>
        </div>
        <div style="margin-top:4.5pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 4.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1.5pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.85pt;left:23.98pt;height:30pt;width:706.02pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="text-align:justify; width:706pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:8pt;">
          <font style="letter-spacing:-0.08pt;">The information in this preliminary prospectus is not complete and may be changed. The selling stockholders may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any state where such offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.08pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-bottom:21.86pt;margin-left:63pt;width:505.31pt;">
        <div style="text-align:center; width:505.31pt; line-height:12pt;font-weight:bold;color:#FC0014;">
          <font style="letter-spacing:-0.2pt;">SUBJECT TO COMPLETION, DATED NOVEMBER&#160;26, 2025</font><font style="font-weight:normal;color:#000000;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:505.31pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:505.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">8,454,514 Shares</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:505.31pt;">
          <img src="lg_altoneurosci-4clr.jpg" alt="[MISSING IMAGE: lg_altoneurosci-4clr.jpg]" height="62" width="194" >
        </div>
        <div style="margin-top:12.52pt; text-align:center; width:505.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock Offered by the Selling Stockholders</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:505.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus relates to the proposed resale from time to time of up to 8,454,514 shares, or the Shares, of our common stock, par value $0.0001 per share, or the common stock, by the selling stockholders named herein, together with any additional selling stockholders listed in a prospectus supplement (together with any of such stockholders&#8217; transferees, pledgees, donees or successors), which consist of (i)&#160;3,832,263 shares of our common stock held by the selling stockholders and (ii)&#160;4,622,251 shares of our common stock issuable upon the exercise of outstanding pre-funded warrants, or the Pre-Funded Warrants, to purchase shares of our common stock held by certain of the selling stockholders. We will not receive any proceeds from the sale of the shares offered by this prospectus, except the exercise price of $0.0001 per share of any of the Pre-Funded Warrants exercised for cash. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:505.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders acquired the Shares in a private placement transaction that closed on October&#160;21, 2025, or the Private Placement. We are filing this Registration Statement on Form S-3, of which this prospectus forms a part, to fulfill our contractual obligations with the selling stockholders to provide for the resale by the selling stockholders of the Shares. See &#8220;Selling Stockholders&#8221; beginning on page 11 of this prospectus for more information about the selling stockholders. The registration of the Shares to which this prospectus relates does not require the selling stockholders to sell any of their Shares, including any shares of common stock issuable upon the exercise of Pre-Funded Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:505.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are not offering any Shares under this prospectus and will not receive any proceeds from the sale or other disposition of the Shares covered hereby; however, we will receive proceeds from the exercise of the Pre-Funded Warrants. See &#8220;Use of Proceeds&#8221; beginning on page 10 of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:505.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may offer and sell or otherwise dispose of the Shares described in this prospectus from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The selling stockholders will bear all selling commissions applicable to the sales of Shares and all fees and expenses of legal counsel for the selling stockholders, subject to certain specified exceptions. We will bear all other costs, expenses and fees in connection with the registration of the Shares. See the section titled &#8220;Plan of Distribution&#8221; for more information about how the selling stockholders may sell or dispose of its Shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:505.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on the New York Stock Exchange under the trading symbol &#8220;ANRO.&#8221; On November&#160;25, 2025, the closing price of our common stock was $13.36 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:505.31pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are an &#8220;emerging growth company&#8221; as defined by the Jumpstart Our Business Startups Act of 2012, and as such, have elected to comply with reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements in future filings.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:505.31pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our securities involves a high degree of risk. Before making an investment decision, you should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; on page <a href="#tRIFA">7</a> of this prospectus as well as those contained in the applicable prospectus supplement and in any free writing prospectuses we may authorize for use in connection with a specific offering, and under similar headings in the other documents that are incorporated by reference into this prospectus.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:505.31pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:68.87pt; text-align:center; width:505.31pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The date of this prospectus is&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2025.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:404pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:188.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">ii</a></font><a href="#tATP"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU">1</a></font><a href="#tPRSU"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHOF"><font style="letter-spacing:0.2pt;">THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHOF">6</a></font><a href="#tTHOF"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">7</a></font><a href="#tRIFA"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">8</a></font><a href="#tSNRF"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">10</a></font><a href="#tUOP"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSEST"><font style="letter-spacing:0.2pt;">SELLING STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSEST">11</a></font><a href="#tSEST"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">15</a></font><a href="#tPOD"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">17</a></font><a href="#tLEMA"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">17</a></font><a href="#tEXP"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">17</a></font><a href="#tWYCF"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCI"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCI">17</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:260pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, using a &#8220;shelf&#8221; registration process. Under this shelf registration process, the selling stockholders may from time to time sell the shares of common stock described in this prospectus in one or more offerings or otherwise as described under &#8220;Plan of Distribution.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus may be supplemented from time to time by one or more prospectus supplements. Such prospectus supplement may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement, you must rely on the information in the prospectus supplement. You should carefully read both this prospectus and any applicable prospectus supplement together with additional information described under the heading &#8220;Where You Can Find Additional Information&#8221; before deciding to invest in any shares being offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the selling stockholders have authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus or in any related prospectus supplement or any free writing prospectus that we have authorized. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Shares are not being offered in any jurisdiction where the offer is not permitted. You should not assume that the information contained in or incorporated by reference in this prospectus is accurate as of any date other than the respective dates of such document. Our business, financial condition, results of operations and prospects may have changed since those dates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise stated, all references in this prospectus to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the company,&#8221; &#8220;Alto&#8221; and &#8220;Alto Neuroscience,&#8221; and similar designations, except where the context requires otherwise, refer to Alto Neuroscience, Inc. We own various U.S. federal trademark applications and unregistered trademarks, including our company name. All other trademarks or trade names referred to in this prospectus, including any relating to a selling stockholder, are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> and </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;">, but such references should not be construed as any indication that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">This summary highlights selected information from this prospectus or incorporated by reference in this prospectus and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; and under similar headings in our SEC filings, including the documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Through insights derived from our scalable and proprietary Precision Psychiatry Platform, or our Platform, we aim to discover brain-based biomarkers to better identify which patients are more likely to respond to our novel product candidates. Our current pipeline consists of seven clinical-stage assets addressing high-need therapeutic areas, focusing on major depressive disorder, or MDD, bipolar depression, or BPD, treatment resistant depression, or TRD, and schizophrenia. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our clinical-stage product candidates are being advanced based on extensive preclinical and clinical data that suggest the potential to bring significant improvements to patient populations not adequately treated with current standard-of-care medications. </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our pipeline of clinical-stage product candidates is depicted below: </font>
          </div>
          <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
            <img src="tb_product-4c.jpg" alt="[MISSING IMAGE: tb_product-4c.jpg]" height="423" width="604" >
          </div>
          <div style="margin-top:16.6pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Private Placement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On October&#160;19, 2025, we entered into a Securities Purchase Agreement, or the Purchase Agreement, with certain institutional and other accredited investors, or the Purchasers, pursuant to which we agreed to </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">sell and issue to the Purchasers in the Private Placement (i)&#160;3,832,263 shares of our common stock and (ii)&#160;with respect to certain Purchasers, Pre-Funded Warrants to purchase 4,622,251 shares of common stock in lieu of shares of common stock. The purchase price per share of common stock was $5.914 per share, or the Purchase Price, and the purchase price for the Pre-Funded Warrants was the Purchase Price minus $0.0001 per Pre-Funded Warrant. We received gross proceeds of approximately $50.0&#160;million from the Private Placement, before deducting offering expenses payable by us. The closing of the Private Placement occurred on October&#160;21, 2025. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The Pre-Funded Warrants have a per share exercise price of $0.0001, subject to proportional adjustments in the event of stock splits or combinations or similar events. The Pre-Funded Warrants will not expire until exercised in full. The Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving 61&#160;days&#8217; notice to us, but not to any&#160;percentage in excess of 19.9%. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The Shares were not initially registered under the Securities Act of 1933, as amended, or the Securities Act. Based in part upon the representations of the Purchasers in the Purchase Agreement, we relied on the exemption afforded by Regulation&#160;D under the Securities Act, and corresponding provisions of state securities or &#8220;blue sky&#8221; laws. Each of the Purchasers represented in the Purchase Agreement that it was an &#8220;accredited investor&#8221; as defined in Regulation&#160;D of the Securities Act and that it was acquiring the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof, and appropriate legends were affixed to the securities. The sale of the securities did not involve a public offering and was made without general solicitation or general advertising. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On October&#160;19, 2025, we entered into a Registration Rights Agreement with the Purchasers, or the Registration Rights Agreement, pursuant to which we agreed to prepare and file, within 45&#160;days of the closing of the Private Placement, or the Filing Deadline, one or more registration statements with the SEC to register for resale the Shares, and to cause the applicable registration statements to become effective within a specified period after the Filing Deadline, or the Effectiveness Deadline. We also agreed to use our best efforts to keep such registration statement effective until the earlier of (i)&#160;the date on which the Purchasers shall have resold all the Shares covered thereby pursuant to Rule&#160;144 or pursuant to the initial registration statement; and (ii)&#160;the date on which the Shares may be resold by the Purchasers without registration and without regard to any volume or manner-of-sale limitations by reason of Rule&#160;144, without the requirement for Alto to be in compliance with the current public information requirement under Rule&#160;144 under the Securities Act or any other rule of similar effect. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We granted the Purchasers customary indemnification rights in connection with the registration statement. The Purchasers have also granted us customary indemnification rights in connection with the registration statement. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The registration statement of which this prospectus is a part relates to the offer and resale of the Shares issued to the Purchasers pursuant to the Registration Rights Agreement, including the shares of our common stock issuable upon the exercise of the Pre-Funded Warrants. When we refer to the selling stockholders in this prospectus, we are referring to the Purchasers and, as applicable, any donees, pledgees, assignees, transferees or other successors-in-interest selling the Shares received after the date of this prospectus from the selling stockholders as a gift, pledge, or other non-sale related transfer. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Following the closing of the Private Placement, as of October&#160;21, 2025, we had 31,034,019 shares of common stock outstanding. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Associated with Our Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the section titled &#8220;Risk Factors&#8221; immediately following this prospectus summary and under similar headings in our filings with the SEC which are incorporated by reference in this prospectus. These risks include the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company with a limited operating history and no history of commercializing products and have incurred substantial losses since our inception. We anticipate </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">incurring substantial and increasing losses for the foreseeable future and may never achieve or maintain profitability. </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Preclinical and clinical development involves a lengthy and expensive process, with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed, or on acceptable terms to us, could cause us to delay, limit, reduce, or terminate our product development or future commercialization efforts. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We rely heavily on the biomarker data gathered from our Platform. We currently anticipate that certain of our therapeutic product candidates will require us to develop and obtain FDA approval of a companion diagnostic for such therapeutic product candidates. We expect to initiate discussions with the FDA concerning the development of companion diagnostics at our end of Phase&#160;2 meetings with respect to ALTO-100 and ALTO-300. If the FDA does not agree with our biomarker-based approach, or if we are unable to successfully develop and obtain regulatory approval for certain companion diagnostic tools needed to leverage our Platform, or experience significant delays in doing so, our business will be materially harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain and may prevent us or any future collaboration partners from obtaining approvals for the commercialization of our product candidates, and additional time may be required to obtain marketing authorization for any of our product candidates that we develop as drug/device combination products. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Even if our product candidates receive regulatory approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels, and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates could limit our ability to market those products and decrease our ability to generate revenue. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our business depends on the success of our product candidates, including ALTO-207, ALTO-300, ALTO-100, ALTO-101 and ALTO-203. If we are ultimately unable to successfully commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We rely on, and intend to continue to rely on, our internal clinical development expertise to conduct our current and future clinical trials, including internal teams and systems as well as external vendors and CROs. If our team is unable to execute according to our strategy, comply with regulatory requirements, or run trials effectively, our ability to obtain regulatory approval may be delayed and our business could be materially harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We are currently subject to and may be subject to additional future securities class action litigation. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The terms of our Loan and Security Agreement, as amended, and the Convertible Loan Agreement with The Wellcome Trust Limited place restrictions on our operating and financial flexibility and may cause dilution to our stockholders. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business or result in further dilution to investors in our common stock. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Competitive products may reduce or eliminate the commercial opportunity for our product candidates for our current or future indications. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies are more effective or safer than ours, our ability to develop and successfully commercialize our current products may be adversely affected. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We are dependent on the services of our management and other clinical and scientific personnel, including our internal clinical operations team, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">If we are unable to obtain and maintain sufficient intellectual property protection for our Platform, technologies, and product candidates and any future product candidates we may develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully develop and commercialize our product candidates may be adversely affected. Further, our issued composition of matter patents covering our pharmaceutical product candidates may expire at such a date that our patents may not prevent competitors from developing, making, and marketing a product that is identical to our product candidates after expiration of any applicable regulatory exclusivities. For example, our composition of matter patents covering ALTO-100 expired and patents covering its method of manufacturing are due to expire in 2030; our composition of matter patents in ALTO-202 (compound) expired (in foreign countries) and are due to expire in 2026 (in the United States), and our polymorph composition of matter patents in ALTO-202 are due to expire in 2035; and our composition of matter patents in ALTO-203 are due to expire in 2027, in all cases without taking into account patent term extensions or adjustments, and assuming payment of all applicable maintenance, renewal, and annuity fees. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our rights to develop and commercialize our product candidates, our Platform, or other technologies are subject, in large part, to the terms and conditions of licenses granted to us by others, such as Stanford, Sanofi, and MedRx. The terms of these licenses may be inadequate to protect our competitive position on products or product candidates for a sufficient amount of time. For example, our patent rights under the terms of our exclusive license agreement with Stanford are only exclusive until December&#160;2029, at which time such rights will become nonexclusive, and our rights under certain technology relating to the inventions covered by such patents are nonexclusive. Further, if we fail to comply with our obligations in the agreements under which we in-license or acquire development or commercialization rights to product candidates, or data from third parties, we could lose such rights that are important to our business. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Patent terms may be inadequate to protect our competitive position on products or product candidates for a sufficient amount of time. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We may have conflicts with our current or future licensors or collaborators that could delay or prevent the development or commercialization of our product candidates. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Alto Neuroscience, Inc. was incorporated under the laws of the State of Delaware in March&#160;2019. Our principal executive offices are located at 650 Castro Street, Suite 450, Mountain View, CA 94041. The telephone number at our executive office is (650) 200-0412. Our corporate website address is www.altoneuroscience.com. We do not incorporate the information contained on, or accessible through, our website into this prospectus, and you should not consider it part of this prospectus. Our website address is included in this prospectus as an inactive textual reference only. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company and a Smaller Reporting Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including relief from the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended, less extensive disclosure obligations regarding executive compensation in our registration statements, periodic reports and proxy statements, exemptions from the requirements to hold a nonbinding advisory vote on executive compensation, and exemptions from stockholder approval of any golden parachute payments not previously approved. We may also elect to take advantage of other reduced reporting requirements in future filings. As a result, our stockholders may not have access to certain information that they may deem important and the information that we provide to our </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">stockholders may be different than, and not comparable to, information presented by other public reporting companies. We could remain an emerging growth company until the earlier of (i)&#160;the last day of the fiscal year following the fifth anniversary of the closing of our initial public offering, (ii)&#160;the last day of the fiscal year in which we have total annual gross revenue of at least $1.235&#160;billion, (iii)&#160;the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0&#160;million as of the last business day of the second fiscal quarter of such year or (iv)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition, the JOBS Act provides that an emerging growth company may take advantage of the extended transition period provided in the Securities Act for complying with new or revised accounting standards. An emerging growth company may therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, as a result, will not be subject to the same implementation timing for new or revised accounting standards as are required of other public companies that are not emerging growth companies, which may make comparison of our consolidated financial information to those of other public companies more difficult. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are also a &#8220;smaller reporting company,&#8221; as defined in the Exchange Act. We will continue to be a smaller reporting company even after we cease to be an emerging growth company, as long as (i)&#160;the market value of our common stock held by non-affiliates is less than $250.0&#160;million measured on the last business day of our second fiscal quarter or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700.0&#160;million measured on the last business day of our second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Common Stock Offered by the Selling Stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">8,454,514 Shares (consisting of (i)&#160;3,832,263 outstanding shares of our common stock and (ii)&#160;4,622,251 shares of our common stock issuable upon the exercise of the Pre-Funded Warrants). </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Use of Proceeds</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The selling stockholders will receive all of the proceeds from the sale of the Shares hereunder. Accordingly, we will not receive any of the proceeds from the sale of the Shares in this offering; however, we will receive proceeds from any cash exercise of the Pre-Funded Warrants. See &#8220;Use of Proceeds.&#8221; </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Risk Factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">An investment in our common stock involves a high degree of risk. See the information contained in or incorporated by reference in the section titled &#8220;Risk Factors&#8221; and under similar headings in the other documents that are incorporated by reference herein, as well as the other information included in or incorporated by reference in this prospectus. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">New York Stock Exchange Symbol</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our common stock is listed on the New York Stock Exchange under the symbol &#8220;ANRO.&#8221;</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:452pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. Before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part, you should consider carefully the risks and uncertainties contained in our most recent Annual Report on Form&#160;10-K and in our subsequent Quarterly Reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety. The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and the documents we have filed with the SEC that are incorporated by reference herein contain forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act, and the Private Securities Litigation Reform Act of 1995, as amended, about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this prospectus and the documents we have filed with the SEC that are incorporated by reference herein, including statements regarding our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, or intentions relating to product candidates and markets and business trends, are forward-looking statements. Discussions containing these forward-looking statements may be found, among other places under the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contained in the documents incorporated by reference herein. We have based these forward-looking statements largely on our current expectations and projections. In some cases, you can identify forward-looking statements because they contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;shall,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these words or other similar terms or expressions. These statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the initiation, timing, progress, and results of our research and development programs, preclinical studies, any clinical trials, and Investigational New Drug and other regulatory submissions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the ability of our approach to reproducibly predict treatment outcomes for product candidates amongst identified patient populations and achieve clinical success; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to continue to identify appropriate biomarkers for use in further clinical development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of and costs involved in obtaining and maintaining regulatory approval of our current product candidates and any future product candidates that we may identify or develop; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the beneficial characteristics, including potential safety, efficacy, and therapeutic effects, of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to efficiently and cost-effectively conduct our current and future clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements, including our ability to comply with our financial obligations pursuant to the terms of such agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing and likelihood of the achievement of milestones pursuant to our existing collaboration and licensing agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify and develop product candidates for treatment of additional indications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the performance of our third-party service providers, including our suppliers and manufacturers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rate and degree of market acceptance and clinical utility for our current product candidates and any other product candidates we may develop; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the effects of competition with respect to our current product candidates or any of our future product candidates, as well as innovations by current and future competitors in our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimates regarding the potential market opportunities and the number of patients for our product candidates and any future product candidates, if approved for commercial use; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the implementation of our strategic plans for our business, any product candidates we may develop; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our intellectual property position, including the scope of protection we are able to establish, maintain, defend and enforce for intellectual property rights covering our product candidates and our Precision Psychiatry Platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to attract and retain key scientific or management personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">regulatory and legal developments in the United States and foreign countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to attract and retain employees and collaborators with development, regulatory, and commercialization expertise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to comply with the terms of our loan agreements and our expectations regarding our ability to access additional tranches thereunder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the accuracy of our estimates regarding future expenses, future revenue, capital requirements, and need for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the anticipated impact of global economic uncertainty, financial market conditions and geopolitical events, including the conflict between Ukraine and Russia, the regional conflict in the Middle East, geopolitical tensions, high levels of inflation, fluctuating interest rates, and tariffs on our business, results of operations, and financial condition; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our use of cash and other resources; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings we make with the SEC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date the statement is made and are subject to risks and uncertainties. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the statement is made, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We discuss many of the risks associated with the forward-looking statements in greater detail under the heading &#8220;Risk Factors&#8221; included in our most recent Annual Report on Form 10-K and in our subsequent Quarterly Reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety. You should evaluate all forward-looking statements in the context of these risks and uncertainties. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should carefully read this prospectus, together with the documents we have filed with the SEC that are incorporated by reference, with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events, or otherwise. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders will receive all of the proceeds from the sale of the Shares hereunder. Accordingly, we will not receive any of the proceeds from the sale of the Shares in this offering; however, we will receive nominal proceeds from any cash exercise of the Pre-Funded Warrants. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSEST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SELLING STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have prepared this prospectus to allow the selling stockholders to offer and sell from time to time up to 8,454,514 shares of our common stock for their own account, consisting of (i)&#160;up to 3,832,263 shares of common stock issued to the selling stockholders and (ii)&#160;4,622,251 shares of common stock issuable to certain of the selling stockholders upon the exercise of the Pre-Funded Warrants pursuant to the Purchase Agreement, without giving effect to any beneficial ownership limitation contained in any Pre-Funded Warrant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are registering the offer and sale of the Shares to satisfy certain registration obligations that we granted the selling stockholders in the Registration Rights Agreement in connection with the purchase of the Shares pursuant to the Purchase Agreement. Under the terms of the Registration Rights Agreement, we agreed to prepare and file by the Filing Deadline, one or more registration statements with the SEC to register for resale the Shares, and to cause the applicable registration statements to become effective by the Effectiveness Deadline. We also agreed to use our best efforts to keep such registration statement effective until the earlier of (i)&#160;the date on which the Purchasers shall have resold all the Shares covered thereby pursuant to Rule&#160;144 or pursuant to the initial registration statement; and (ii)&#160;the date on which the Shares may be resold by the Purchasers without registration and without regard to any volume or manner-of-sale limitations by reason of Rule&#160;144, without the requirement for Alto to be in compliance with the current public information requirement under Rule&#160;144 under the Securities Act or any other rule of similar effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth, to our knowledge, information concerning the beneficial ownership of shares of our common stock by the selling stockholders as of October&#160;31, 2025. Beneficial ownership is determined in accordance with the rules of the SEC, and includes voting or investment power with respect to our common stock. Generally, a person &#8220;beneficially owns&#8221; shares of our common stock if the person has or shares with others the right to vote those shares or to dispose of them, or if the person has the right to acquire voting or disposition rights within 60&#160;days. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that each selling stockholder named in the table below has sole voting and investment power with respect to all shares of common stock that they beneficially own, subject to applicable community property laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of common stock beneficially owned by each selling stockholder as of October&#160;31, 2025 includes all shares of our common stock purchased by such selling stockholder in the Private Placement. The Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving 61&#160;days&#8217; notice to us, but not to any&#160;percentage in excess of 19.9%. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of common stock that may be offered under this prospectus includes (x)&#160;all shares of our common stock purchased by such selling stockholder in the Private Placement and (y)&#160;all shares of our common stock underlying Pre-Funded Warrants purchased by such selling stockholder in the Private Placement, without giving effect to the beneficial ownership limitation. The number of shares of common stock beneficially owned by each selling stockholder following the offering assumes all of the Shares covered hereby are sold and such stockholder does not acquire beneficial ownership of any additional shares of common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The&#160;percentage of shares owned before and after the offering are based on 31,066,329 shares of our common stock outstanding as of October&#160;31, 2025, which includes the outstanding shares of common stock offered by this prospectus but does not include any shares of common stock offered by this prospectus that are issuable pursuant to the Pre-Funded Warrants, and assumes the selling stockholders dispose of all of the Shares covered by this prospectus and do not acquire beneficial ownership of any additional shares of common stock. The registration of the Shares does not necessarily mean that the selling stockholders will sell all or any portion of the Shares covered by this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may sell some, all or none of the Shares offered by this prospectus from time to time. We do not know how long the selling stockholders will hold the Shares covered hereby before selling them and we currently have no agreements, arrangements or understandings with the selling stockholders regarding the sale or other disposition of any Shares. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As used in this prospectus, the term &#8220;selling stockholders&#8221; includes the selling stockholders listed in the table below, together with any additional selling stockholders listed in a prospectus supplement, and their donees, pledgees, assignees, transferees, distributees and successors-in-interest that receive Shares in any non-sale transfer after the date of this prospectus. </font>
        </div>
        <table style="width:456pt;height:154pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:217.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Beneficial Ownership Prior</font>
                <br >
                <font style="letter-spacing:-0.16pt;">to this Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Beneficial Ownership After</font>
                <br >
                <font style="letter-spacing:-0.16pt;">this Offering</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:217.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Selling Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares Being</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offered</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:217.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Perceptive Life Sciences Master Fund, Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.925000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">3,227,181</td>
            <td style="padding:0pt;padding-left:0.925000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">9.99<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,536,354</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.920000000000002pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,989,393</td>
            <td style="padding:0pt;padding-left:0.920000000000002pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.92<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Commodore Capital Master LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.925000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">3,214,848 </td>
            <td style="padding:0pt;padding-left:0.925000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">9.99<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,536,354</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.920000000000002pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,100,511</td>
            <td style="padding:0pt;padding-left:0.920000000000002pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.38<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:217.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Point72 Asset Management</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.925000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2,816,868</td>
            <td style="padding:0pt;padding-left:0.925000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.91<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,099,087</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.920000000000002pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,717,781</td>
            <td style="padding:0pt;padding-left:0.920000000000002pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.43<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Vestal Point Capital, LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.925000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2,482,358</td>
            <td style="padding:0pt;padding-left:0.925000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.99<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,606,358</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.920000000000002pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">876,000</td>
            <td style="padding:0pt;padding-left:0.920000000000002pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.82<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Vivo</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.925000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,030,322</td>
            <td style="padding:0pt;padding-left:0.925000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.32<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">676,361</td>
            <td style="padding:0pt;padding-left:1.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.920000000000002pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">353,961</td>
            <td style="padding:0pt;padding-left:0.920000000000002pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.14<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents beneficial ownership of less than 1% </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Assumes each selling stockholder sells the maximum number of shares of our common stock possible in this offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents all of the shares of our common stock that the selling stockholders may offer and sell from time to time under this prospectus without giving effect to the beneficial ownership limitation in the Pre-Funded Warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The shares reported under &#8220;Beneficial Ownership Prior to this Offering&#8221; consists of (i)&#160;1,989,393 shares of common stock and (ii)&#160;1,237,788 shares of common stock issuable upon the exercise of Pre-Funded Warrants held by Perceptive Life Sciences Master Fund, Ltd, or the Perceptive Master Fund. Due to a beneficial ownership blocker in the Pre-Funded Warrants, the number of shares beneficially owned prior to the offering excludes 1,298,566 shares of common stock issuable upon the exercise of Pre-Funded Warrants held by the Perceptive Master Fund. The number of shares being offered consists of 2,536,354 shares of common stock issuable upon the exercise of Pre-Funded Warrants held by the Perceptive Master Fund. Perceptive Advisors LLC (&#8220;Perceptive Advisors&#8221;) is the investment advisor of the Perceptive Master Fund and may be deemed to have beneficial ownership of the shares beneficially owned thereby. Joseph Edelman is the controlling person of Perceptive Advisors and accordingly, may be deemed to have beneficial ownership of the shares beneficially owned by the Perceptive Master Fund and Perceptive Advisors. Perceptive Advisors, the Perceptive Master Fund and Mr.&#160;Edelman disclaim beneficial ownership of all such securities except to the extent of its or his pecuniary interest therein. The business address for each of Perceptive Advisors, the Perceptive Master Fund and Mr.&#160;Edelman is 51&#160;Astor Place, 10th Floor, New York, NY 10003. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The shares reported under &#8220;Beneficial Ownership Prior to this Offering&#8221; consists of (i)&#160;2,100,511 shares of common stock and (ii)&#160;1,114,337 shares of common stock issuable upon the exercise of Pre-Funded Warrants held by Commodore Capital Master LP. The number of shares being offered consists of 1,000,000 shares of common stock and 1,536,354 shares of common stock issuable upon the exercise of Pre-Funded Warrants held by Commodore Capital Master LP. Due to a beneficial ownership blocker in the Pre-Funded Warrants, the number of shares beneficially owned prior to the offering excludes 422,017 shares of common stock issuable upon the exercise of Pre-Funded Warrants held by Commodore Capital Master LP. Commodore Capital LP is the investment manager to Commodore Capital Master LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion with respect to these shares. Commodore Capital LP and Commodore Capital Master LP have shared voting and dispositive power with respect to the shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The shares reported under &#8220;Beneficial Ownership Prior to this Offering&#8221; consists of 667,778 shares of common stock held by Point72 Biotech Private Investments, LLC, or Point72 Biotech, and (i)&#160;1,599,547 shares of our common stock and (ii)&#160;549,543 shares of common stock issuable upon the exercise of Pre-Funded Warrants held by Point72 Associates, LLC, or Point72 Associates. Differentiated Ventures Investments, LLC, or Differentiated Ventures, is the managing member of Point72 Biotech and may be deemed to share beneficial ownership of the shares held by Point72 Biotech. 72 Investment Holdings, LLC, or 72 Investment Holdings, is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of which Differentiated Ventures may be deemed to share beneficial ownership. Steven A. Cohen, or Mr.&#160;Cohen, is the sole member of 72 Investment Holdings and may be deemed to share beneficial ownership of the shares of which 72 Investment Holdings may be deemed to share beneficial ownership. Each of Differentiated Ventures, 72 Investment Holdings and Mr.&#160;Cohen disclaims beneficial ownership of the shares held by Point72 Biotech. Pursuant to an investment management agreement, Point72 Asset Management, L.P., or Point72 Asset Management, maintains investment and voting power with respect to the shares held by Point72 Associates and therefore may be deemed to share beneficial ownership of such shares. Point72 Capital Advisors, Inc., or Point72 Capital Advisors, is the general partner of Point72 Asset Management and may be deemed to share beneficial ownership of the shares of which Point72 Asset Management may be deemed to share beneficial ownership. Mr.&#160;Cohen is the sole member of Point72 Capital Advisors and may be deemed to share beneficial ownership of the shares of which Point72 Capital Advisors may be deemed to share beneficial ownership. Each of Point72 Asset Management, Point72 Capital Advisors and Mr.&#160;Cohen disclaims beneficial ownership of the shares held by Point72 Associates. The address for Point72 Biotech and Point72 Associates is c/o&#160;Point72, L.P., 72 Cummings Point Road, Stamford, CT 06902. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The shares reported under &#8220;Beneficial Ownership Prior to this Offering&#8221; consists of (i)&#160;1,258,484 shares of common stock held by Vestal Point Master Fund&#160;LP, or Vestal Point Master Fund and (ii)&#160;1,223,874 shares of common stock held by accounts separately managed by Vestal Point Capital, LP, or Vestal Point Capital. The number of shares being offered consists of 813,168 shares of common stock held by Vestal Point Master Fund and 793,190 shares of common stock held by accounts separately managed by Vestal Point Capital. The sole general partner of Vestal Point Master Fund, LP is Vestal Point Partners GP, LLC. The managing member of Vestal Point Partners GP, LLC is Ryan Wilder. The sole general partner of Vestal Point Capital, LP is Vestal Point Capital, LLC. The managing member of Vestal Point Capital, LLC is Mr.&#160;Wilder. As a result, Mr.&#160;Wilder may be deemed to have voting and investment power over the securities held by Vestal Point Master Fund, LP and the accounts separately managed by Vestal Point Capital, LP. Mr.&#160;Wilder disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The address of the foregoing entities and Mr.&#160;Wilder is c/o&#160;Vestal Point Capital, LP, 632 Broadway, Suite 602, New York, NY 10012. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The shares reported under &#8220;Beneficial Ownership Prior to this Offering&#8221; consists of (i)&#160;935,813 shares of common stock held by Vivo Opportunity Fund&#160;Holdings, LP, or Vivo and (ii)&#160;94,509 shares of common stock held by Vivo Opportunity Cayman Fund, LP, or Vivo Cayman. The number of shares being offered consists of 614,310 shares of common stock held by Vivo and 62,051 shares of common stock held by Vivo Cayman. Vivo Opportunity, LLC is the general partner of Vivo and may be deemed to share voting, investment and dispositive power over the shares held by Vivo. Vivo Opportunity Cayman, LLC is the general partner of Vivo Cayman and may be deemed to share voting, investment and dispositive power over the shares held by Vivo Cayman. The voting members of each of Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC are Kevin Dai, Gaurav Aggarwal, Frank Kung and Shan Fu, none of whom has individual voting or investment power with respect to the shares held by Vivo or Vivo Cayman. The address of each of the individuals and entities referenced in this footnote is c/o&#160;Vivo Capital LLC, 192 Lytton Avenue, Palo Alto, California 94301. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Relationships with Selling Stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of the selling stockholders has not had any material relationship with the registrant or any of its predecessors or affiliates, within the past three&#160;years, except as hereinafter described. As discussed in greater detail above under the section titled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Private Placement,&#8221; in October&#160;2025, we entered into the Purchase Agreement with the selling stockholders, pursuant to which we sold and issued shares of our common stock and Pre-Funded Warrants to purchase our common stock. Pursuant the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:512pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Registration Rights Agreement, we agreed to prepare and file, by the Filing Deadline, one or more registration statements with the SEC to register for resale the common stock issued under the Purchase Agreement and the shares of common stock issuable upon exercise of the Pre-Funded Warrants issued pursuant to the Purchase Agreement, and to cause the applicable registration statements to become effective by the Effectiveness Deadline. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Entities affiliated with Perceptive Advisors LLC, Commodore Capital Master LP, entities affiliated with Point72 Associates, LLC and entities affiliated with Vestal Point Capital, LP are, and prior to the Private Placement entities affiliated with Perceptive Advisors LLC and entities affiliated with Point72 Associates, LLC have been, beneficial owners of more than 5% of our common stock. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">distributions to members, partners, stockholders or other equityholders of the selling stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an exchange distribution in accordance with the rules of the applicable exchange; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">privately negotiated transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">short sales and settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a combination of any such methods of sale; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other method permitted pursuant to applicable law. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule&#160;424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees, or other successors in interest will be the selling stockholders for purposes of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:68pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the Pre-Funded Warrants by payment of cash, however, we will receive the exercise price of the Pre-Funded Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule&#160;144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be &#8220;underwriters&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act (it being understood that the selling stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering). Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &#8220;underwriters&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have advised the selling stockholders that the anti-manipulation rules of Regulation&#160;M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares of common stock offered by this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed with the selling stockholders to use commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of: (i)&#160;date on which the selling stockholders shall have resold or otherwise disposed of all the shares covered by this prospectus pursuant to Rule&#160;144 or pursuant to this prospectus and (ii)&#160;the date on which the shares covered by this prospectus no longer constitute &#8220;Registrable Securities&#8221; as such term is defined in the Registration Rights Agreement, such that they may be resold by the selling stockholders without registration and without regard to any volume or manner-of-sale limitations and without current public information pursuant to Rule&#160;144 under the Securities Act or any other rule of similar effect. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a><a name="tIOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cooley LLP will pass upon the validity of the securities offered by this prospectus, and any supplement thereto, unless otherwise indicated in the applicable prospectus supplement. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. As of the date of this prospectus, partners of Cooley LLP and GC&amp;H Investments, LLC, an entity comprising partners and associates of Cooley LLP, beneficially own 57,569 shares of common stock. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The financial statements incorporated by reference in this prospectus have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm, given their authority as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities being offered under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at http://www.sec.gov. In addition, we maintain a website that contains information about us at www.altoneuroscience.com. The information found on, or otherwise accessible through our website is not incorporated by reference into, and does not form a part of, this prospectus or any other document or report we file or furnish with the SEC. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to incorporate by reference information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File No. 001-41944): </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000025/alto-20241231.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed with the SEC on March&#160;20, 2025</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the information specifically incorporated by reference into our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000025/alto-20241231.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2024</a> from our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000119312525070446/d936566ddef14a.htm">definitive proxy statement on Schedule&#160;14A, filed with the SEC on April&#160;1, 2025</a>, as <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000119312525116871/d911824ddefr14a.htm">revised on May&#160;9, 2025</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Quarterly Reports on Form 10-Q for the quarters ended March&#160;31, 2025, June&#160;30, 2025, and September&#160;30, 2025, filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000037/alto-20250331.htm">May&#160;14, 2025</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000076/alto-20250630.htm">August&#160;13, 2025</a>, and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000090/alto-20250930.htm">November&#160;12, 2025</a>, respectively; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Current Reports on Form 8-K filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000119312525007383/d891653d8k.htm">January&#160;16, 2025</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000119312525019318/d843857d8k.htm">February&#160;3, 2025</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000119312525024814/d876505d8k.htm">February&#160;12, 2025,</a> <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000024/alto-20250317.htm">March&#160;20, 2025</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000035/alto-20250513.htm">May&#160;14, 2025</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000048/alto-20250531.htm">June&#160;3, 2025</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000053/alto-20250626.htm">June&#160;26, 2025</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000061/alto-20250703.htm">July&#160;8, 2025</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000199948025000075/alto-20250812.htm">August&#160;13, 2025</a>, and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1999480/000110465925100801/tm2529007d1_8k.htm">October&#160;20, 2025</a> (each to the extent the information in such reports is filed and not furnished); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:312pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the description of our common stock contained in our registration statement on <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1999480/000119312524019402/d753789d8a12b.htm">Form 8-A, filed with the SEC on January&#160;30, 2024</a>, as updated by <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1999480/000199948025000025/exhibit45-descriptionofsec.htm">Exhibit&#160;4.5</a> of our Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed with the SEC on March&#160;20, 2025, including any amendments or reports filed for the purpose of updating such description. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also incorporate by reference any future filings (other than current reports furnished under Item&#160;2.02 or Item&#160;7.01 of Form 8-K and exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus, which will become a part of this prospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later-filed document modify or replace such earlier statements. We will furnish without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to: </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Alto Neuroscience, Inc. </font>
          <br >
          <font style="letter-spacing:0.2pt;">Attn: Corporate Secretary </font>
          <br >
          <font style="letter-spacing:0.2pt;">650 Castro Street, Suite 450 </font>
          <br >
          <font style="letter-spacing:0.2pt;">Mountain View, CA 94041 </font>
          <br >
          <font style="letter-spacing:0.2pt;">(650) 200-0412</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:158pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">8,454,514 Shares</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:98pt; text-align:center; width:456pt;">
          <img src="lg_altoneurosci-4clr.jpg" alt="[MISSING IMAGE: lg_altoneurosci-4clr.jpg]" height="69" width="215" >
        </div>
        <div style="margin-top:77pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:96pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">PROSPECTUS</font>
        </div>
        <div style="margin-top:158.833pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 158.833333333333pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:137pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PART II</font>
          <br >
          <font style="letter-spacing:-0.2pt;">INFORMATION NOT REQUIRED IN THE PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;14.&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the estimated costs and expenses to be incurred in connection with the sale and distribution of the securities being registered hereby, all of which will be borne by the Registrant (except any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of its shares). All amounts shown are estimates, except for the SEC registration fee. </font>
        </div>
        <table style="width:416pt;height:84pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.29pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">15,248 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">75,000 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">100,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printing and miscellaneous expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">14,752 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">205,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;15.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are incorporated under the laws of the State of Delaware. Section&#160;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#8217;s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. Our amended and restated certificate of incorporation permits indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and our amended and restated bylaws provide that we will indemnify our directors and executive officers and permit us to indemnify our other officers, employees and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered into indemnification agreements with our directors and executive officers, whereby we have agreed to indemnify our directors and executive officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or executive officer was, or is threatened to be made, a party by reason of the fact that such director or executive officer is or was a director, executive officer, employee, or agent of Alto Neuroscience, Inc., provided that such director or executive officer acted in good faith and in a manner that the director or executive officer reasonably believed to be in, or not opposed to, the best interest of Alto Neuroscience, Inc. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his capacity as such. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;16.&nbsp;&nbsp;&nbsp;Exhibits</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:268pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:29.01pt;" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Exhibit</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:204.01pt;" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Incorporated by Reference </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:17.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Form </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:43.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">File No. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:24.75pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.13pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:45.62pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Filing Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:29.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:204.01pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1999480/000119312524025266/d736911dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant</a>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:17.97pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8-K </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:43.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">001-41944 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:24.75pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:45.62pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2/6/2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:29.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:204.01pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1999480/000119312524025266/d736911dex32.htm">Amended and Restated Bylaws of the Registrant</a>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17.97pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8-K </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:43.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">001-41944 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:24.75pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:45.62pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2/6/2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:29.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:204.01pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/tm2529007d1_ex10-2.htm">Form of Registration Rights Agreement, dated October&#160;19, 2025</a>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17.97pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8-K </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:43.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">001-41944 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:24.75pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">10.2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:45.62pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">10/20/2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:29.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204.01pt;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/tm2529007d1_ex4-1.htm">Form of Pre-Funded Warrant</a>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17.97pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8-K </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">001-41944 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24.75pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:45.62pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">10/20/2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:29.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5.1* </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204.01pt;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2531771d2_ex5-1.htm">Opinion of Cooley LLP</a>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:17.97pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:43.34pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24.75pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:45.62pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:29.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">10.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:204.01pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/tm2529007d1_ex10-1.htm">Form of Securities Purchase Agreement, by and among the Registrant and the Purchasers, dated October&#160;19, 2025</a>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17.97pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8-K </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:43.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">001-41944 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:24.75pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">10.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:45.62pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">10/20/2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:29.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">23.1* </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:204.01pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2531771d2_ex5-1.htm">Consent of Cooley LLP (included in Exhibit&#160;5.1)</a>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:17.97pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:43.34pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24.75pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:45.62pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:29.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">23.2* </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:204.01pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2531771d2_ex23-2.htm">Consent of Independent Registered Public Accounting Firm</a>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:17.97pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:43.34pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24.75pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:45.62pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:29.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">24.1* </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:204.01pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a href="#tSIG">Power of Attorney (included on signature page hereto)</a>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:17.97pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:43.34pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24.75pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:45.62pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:29.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">107* </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:204.01pt;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2531771d1_ex-filingfees.htm">Filing Fee Table</a>
              </div>
            </td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:17.97pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:43.34pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24.75pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt; width:9.13pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:45.62pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.69pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Filed herewith. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;17.&nbsp;&nbsp;&nbsp;Undertakings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(1)&nbsp;&nbsp;&nbsp;To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;To include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Provided, however, that the undertakings set forth in paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of the registration statement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:88pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(2)&nbsp;&nbsp;&nbsp;That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(3)&nbsp;&nbsp;&nbsp;To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(4)&nbsp;&nbsp;&nbsp;That, for the purpose of determining liability under the Securities Act to any purchaser: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;Each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;Each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii), or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(5)&nbsp;&nbsp;&nbsp;That, for purposes of determining any liability of under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSIG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mountain View, State of California, on this 26</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> day of November, 2025. </font>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ALTO NEUROSCIENCE, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:240pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">/s/ Amit Etkin </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Amit Etkin, M.D., Ph.D. </font>
          <br >
          <font style="letter-spacing:0.2pt;">President and Chief Executive Officer </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">POWER OF ATTORNEY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">KNOW ALL PERSONS BY THESE PRESENTS</font><font style="letter-spacing:0.2pt;">, that each person whose signature appears below constitutes and appoints Amit Etkin, M.D., Ph.D. and Nicholas Smith, and each of them, as true and lawful attorneys-in-fact and agents, each with the full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing pursuant to Rule&#160;462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and generally to do all such things in their names and behalf in their capacities as officers and directors to enable Alto Neuroscience, Inc. to comply with the provisions of the Securities Act of 1933 and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated. </font>
        </div>
        <table style="width:456pt;height:233.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174.83pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signatures </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174.83pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:82.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:51.25pt; white-space:normal;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.833pt 0pt; width:174.83pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Amit Etkin</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 174.83pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Amit Etkin, M.D., Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.833pt 0pt; width:174.83pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">President, Chief Executive Officer, and Chair of the Board of Directors </font><font style="font-style:italic;letter-spacing:0.2pt;">(Principal Executive Officer)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.833pt 0pt; width:82.34pt;white-space:nowrap;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">November&#160;26, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:51pt; white-space:normal;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.833pt 0pt; width:174.83pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Nicholas Smith</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 174.83pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Nicholas Smith </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.833pt 0pt; width:174.83pt;">
              <div style="text-align:center;font-style:italic;">
                <font style="font-style:normal;letter-spacing:0.2pt;">Chief Financial Officer </font><font style="letter-spacing:0.2pt;">(Principal Financial Officer and Principal Accounting Officer)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.833pt 0pt; width:82.34pt;white-space:nowrap;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">November&#160;26, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:41pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:174.83pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Christopher Nixon Cox</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 174.83pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Christopher Nixon Cox </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:174.83pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:82.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">November&#160;26, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:41pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:174.83pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Andrew Dreyfus</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 174.83pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Andrew Dreyfus </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:174.83pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:82.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">November&#160;26, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:174.83pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Husseini Manji</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 174.83pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Husseini Manji, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:174.83pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:82.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">November&#160;26, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:520.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:90.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174.83pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signatures </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174.83pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:82.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:41.25pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:174.83pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Raymond Sanchez</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 174.83pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Raymond Sanchez, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:174.83pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:82.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">November&#160;26, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:174.83pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Gwill York</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 174.83pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Gwill York </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:174.83pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:82.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">November&#160;26, 2025</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm2531771d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2531771d2_ex5-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Courtney M.W. Tygesson&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T +1 312 881 6680&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CTygesson@cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November&nbsp;26, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alto Neuroscience,&nbsp;Inc.<BR>
650 Castro Street, Suite&nbsp;450&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mountain View, CA 94041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to Alto Neuroscience,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the filing of a Registration Statement on Form&nbsp;S-3
(the &ldquo;<B><I>Registration Statement</I></B>&rdquo;) with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;), including a related prospectus included
in the Registration Statement (the &ldquo;<B><I>Prospectus</I></B>&rdquo;), covering the registration for resale of up to 8,454,514 shares
of the Company&rsquo;s common stock, par value $0.0001 per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;), consisting of (a)&nbsp;3,832,263
shares (the &ldquo;<B><I>Shares</I></B>&rdquo;) of Common Stock that are currently outstanding and (b)&nbsp;up to 4,622,251 shares (the
 &ldquo;<B><I>Warrant Shares</I></B>&rdquo;) of Common Stock issuable upon the exercise of pre-funded warrants to purchase shares of Common
Stock (the &ldquo;<B><I>Warrants</I></B>&rdquo;). The Shares and the Warrants were issued by the Company pursuant to that certain Securities
Purchase Agreement, dated October&nbsp;19, 2025, by and between the Company and the purchasers named therein (the &ldquo;<B><I>Purchase
Agreement</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this opinion, we have examined
and relied upon the Registration Statement, the Prospectus, the Company&rsquo;s certificate of incorporation and bylaws, each as currently
in effect, the Purchase Agreement, the form of the Warrants, and such other records, documents, opinions, certificates, memoranda and
instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness
of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted
to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution
and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate
of an officer of the Company and have not independently verified such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our opinion is expressed only with respect to
the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject
matter hereof and express no opinion and provide no assurance as to compliance with any federal or state anti-fraud law, rule&nbsp;or
regulation relating to securities or to the sale or issuance thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the Warrant Shares, we express
no opinion to the extent that future issuances of securities of the Company, adjustments to outstanding securities of the Company or other
matters cause the Warrants to be exercisable for more shares of Common Stock than the number available for issuance by the Company, or
that the consideration paid upon exercise of the Warrants is below the par value per share of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the basis of the foregoing, and in reliance
thereon, we are of the opinion that (i)&nbsp;the Shares are validly issued, fully paid and nonassessable and (ii)&nbsp;the Warrant Shares,
when issued and paid for in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley LLP&ensp; 110 N. Wacker Drive, Suite&nbsp;4200&ensp;
Chicago,&nbsp;IL&ensp; 60606-1511&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">t: (312) 881-6500&ensp; f: (312) 881-6598&ensp;
cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2531771d2_ex5-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> November&nbsp;26, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page&nbsp;Two &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our opinion is limited to the matters expressly
set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This
opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update
or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may
hereafter occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the reference to our firm
under the caption &ldquo;Legal Matters&rdquo; in the Prospectus and to the filing of this opinion as an exhibit to the Registration Statement.
In giving such consents, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7
of the Securities Act or the rules&nbsp;and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Cooley LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">/s/ Courtney M.W. Tygesson</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Courtney M.W. Tygesson &nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley LLP&ensp; 110 N. Wacker Drive, Suite&nbsp;4200&ensp;
Chicago,&nbsp;IL&ensp; 60606-1511&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">t: (312) 881-6500&ensp; f: (312) 881-6598&ensp;
cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>tm2531771d2_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><FONT STYLE="font-style: normal; font-weight: normal">We consent to the incorporation by reference in this Registration
Statement on Form S-3 of our report dated March 20, 2025, relating to the financial statements of Alto Neuroscience, Inc. appearing in
the Annual Report on Form 10-K of Alto Neuroscience, Inc. for the year ended December 31, 2024. We also consent to the reference to us
under the heading &ldquo;Experts&rdquo; in such Registration Statement.</FONT></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B>/s/ Deloitte &amp; Touche LLP</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><FONT STYLE="font-style: normal; font-weight: normal">Chicago, IL</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-style: normal; font-weight: normal">November 26, 2025&nbsp;</FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>tm2531771d1_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
  <head>
    <title>EX-FILING FEES</title>
  </head>
  <body>
    <div style="display: none">
      <ix:header>
        <ix:hidden>
          <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-331">S-3</ix:nonNumeric>
          <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-332">S-3</ix:nonNumeric>
          <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-333">EX-FILING FEES</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-334">0001999480</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-335">Alto Neuroscience, Inc.</ix:nonNumeric>
          <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric>
          <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric>
          <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric>
        </ix:hidden>
        <ix:references>
          <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
        </ix:references>
        <ix:resources>
          <xbrli:context id="rc">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-26</xbrli:startDate>
              <xbrli:endDate>2025-11-26</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_1">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-26</xbrli:startDate>
              <xbrli:endDate>2025-11-26</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="USD">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="pure">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="Shares">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
        </ix:resources>
      </ix:header>
    </div>
    <div>
      <table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
        <tr>
          <td colspan="4" style="padding-bottom: .5em">
            <p>
              <b>Calculation of Filing Fee Tables</b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-363">S-3</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-364">Alto Neuroscience, Inc.</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 1: Newly Registered and Carry Forward Securities</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 12%;">
            <!-- BLANK -->
          </th>
          <th style="width: 2%;">
            <!-- BLANK -->
          </th>
          <th style="width: 12%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 14%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title </b>
            </p>
          </th>
          <th style="width: 2%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Calculation or Carry Forward Rule</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount Registered</b>
            </p>
          </th>
          <th style="width: 15%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Proposed Maximum Offering Price Per Unit</b>
            </p>
          </th>
          <th style="width: 10%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Rate</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Registration Fee</b>
            </p>
          </th>
          <th style="width: 1%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Form Type</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward File Number</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Initial Effective Date</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b>
            </p>
          </th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Newly Registered Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_1" format="ixt:booleanfalse" id="ixv-365">Fees to be Paid</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
		1
	</td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-366">Equity</ix:nonNumeric>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-367">Common stock, par value $0.0001 per share </ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-368">Other</ix:nonNumeric>
          </td>
          <td style="text-align: right;">
            <ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="Shares" decimals="0" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-369">8,454,514</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-370">13.06</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-371">110,415,952.84</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-372">0.0001381</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-373">15,248.44</ix:nonFraction>
          </td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fees Previously Paid
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Carry Forward Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Carry Forward Securities
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; width: 16%;">
            <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-374">110,415,952.84</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; border-bottom: 1px black; width: 16%;">
            <p id="TotalFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-375">15,248.44</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fees Previously Paid:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-376">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fee Offsets:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-377">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Net Fee Due:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="NetFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-378">15,248.44</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
      </table>
    </div>
    <div>
      <table style="width: 100%; text-indent: 0px;">
        <tbody>
          <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
            <td>
              <p style="margin:0pt;text-align:left; margin-bottom: 5px;">
                <b>Offering Note</b>
              </p>
            </td>
            <td/>
          </tr>
        </tbody>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="width: 100%; text-indent: 0px;">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
          <td style="width:10pt;">
            <p style="margin:0pt;text-align:left;">
              <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup>
            </p>
          </td>
          <td colspan="7" style="white-space: pre-line;">
            <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_1" id="ixv-379"> 1. The amount of shares registered represents an aggregate of 8,454,514 shares of Alto Neuroscience, Inc. common stock, par value $0.0001 per share ("common stock"), which includes 4,622,251 shares of common stock that may be issued upon the exercise of pre-funded warrants, held by the selling stockholders named in the prospectus that forms a part of this registration statement (this "Registration Statement"). Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional number of shares of common stock as may be issuable as a result of stock splits, stock dividends, or other distribution, recapitalization or similar events with respect to the shares of common stock being registered pursuant to this Registration Statement. The proposed maximum offering price per share has been estimated in accordance with Rule 457(c) under the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per unit and the maximum aggregate offering price are based on the average of the high and low sale price of common stock, as reported on the New York Stock Exchange on November 24, 2025, which date is within five business days prior to filing this Registration Statement.
</ix:nonNumeric>
          </td>
        </tr>
        <tr>
          <td colspan="7">
            <hr style="width:100%;text-align:left;margin-left:0"/>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 2: Fee Offset Claims and Sources</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center;  border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 10%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 8%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 16%;">
				Registrant or Filer Name
			</th>
          <th style="width: 6%;">
				Form or Filing Type
			</th>
          <th style="width: 7%;">
				File Number
			</th>
          <th style="width: 6%;">
				Initial Filing Date
			</th>
          <th style="width: 6%;">
				Filing Date
			</th>
          <th style="width: 6%;">
				Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Security Type Associated with Fee Offset Claimed
			</th>
          <th style="width: 8%;">
				Security Title Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Unsold Securities Associated with Fee Offset Claimed
			</th>
          <th style="width: 9%;">
				Unsold Aggregate Offering Amount Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Fee Paid with Fee Offset Source
			</th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rules 457(b) and 0-11(a)(2)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rule 457(p)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 3: Combined Prospectuses</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 4%">
            <!-- Note column -->
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 25%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title</b>
            </p>
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 18%">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 6%">
            <p style="margin: 0pt; text-align: center;">
              <b>Form Type</b>
            </p>
          </th>
          <th style="width: 10%">
            <p style="margin: 0pt; text-align: center;">
              <b>File Number</b>
            </p>
          </th>
          <th style="width: 8%">
            <p style="margin: 0pt; text-align: center;">
              <b>Initial Effective Date</b>
            </p>
          </th>
        </tr>
        <tr style="background-color:#E7E7E2;">
          <td style="text-align: center;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
        </tr>
      </table>
    </div>
  </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>lg_altoneurosci-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_altoneurosci-4clr.jpg
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M 0,1 ?_$ ,P   $$ P$!               &!P@) 00% P(! 0 " P$! 0
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MS+JZ\JX?],A=6+J?!*6LRV38!Y<BW.<6W\FYM_;5\)6>YE!=<F;:-3LDOBO
M=C+&J.1\VE+5INS8F*V>A2?H'\? $KPXON<:Q)T9PUHT^\R6[M--2#PWK2O8
M+*OB4H4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
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M)07]*\<1?6[+>7K1AZLM42&0, IAAMM7O@8UCN3>MFO5;NO5]<Y2ZVSJ  ;
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M+]+>9/\  '/ZW'H"S:@"@"@"@"@(#>TO_FNG7Y2Z_N8M 5]4!>;I/^BW)/\
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MK_VS_4>K>:\V-G%N_P!P3W>D+P^&O+M*#_CCW'J.87:>*K3_ %'3CZF9_BI
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M1$>L&T[FYS.+4A& )"1S$JP'@P- .!0'RY^+7\T_%0%"M_\ [=NG]+D?QJJ
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M'CX5!!^&OD[-[&5%?DRHO[=12ZUAXCCY<U7R%FA26;=>&FY:L (LK\W=Q/8
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M:3(<(2VA4Q.#)6HD )YJ6\2=V^@+@* * * * * @-[2[^::=?E+K\46@*^J
MO-TG_1;DG_ K9_5&Z$BQH0% 04]HYI\].L&5M383/%ZI><L]U4E.*@Q+^ECK
M4>Q*5I6C;VK% 5V4!:GT-:Q0L^Z6Q<C3Y*?K9DQ'H:XZB X]:\?S9U(WD(!Y
M*L-W",?.%"25=" H H"N+VA.L,&_7JTZ1V&2F1'R^ZJX9B4V0I N"T<#+!.'
MG--J658'>O [4T!!Z@+%/U>IOZB?J/T9?UMX?KQZ-AY?/\_EX>'T3R</E5!)
M+O/;UWM$)K,UE5Q2+<?SR,K$MO15[%!0':DX$'LVUK^<RK4(*XHZZ?J6R4=O
M<7V41HUINA5U3]+VJ7YFQE7.]FS6RGT9SD7%*<7H+IP<!\*?E)[Q7VRW-Z%[
M'RO">V+U]F]'RS#*JUF_,L8[)+5^1V;G:+7>HRH5WALS8BM[,A <3XQB-GC%
M7JDUJ*RC7J49<5.3B^@:J_\ 3EDNYE;UF>D65]6T(:5SHX/S%[?V]94;N:UZ
M3;;7FV[IZ*B51=.A]Z\!N+OTWYUA<:[5-AW-H>:@E4=Y0\2APC[ZLF-W%ZU@
M;/0YOM)_W(R@^]>(CKAI3J/:U<,G+DIWP&+A)!]ULFOLJ\'M+JEGEA5U54NO
MR^\3LNR7RWJ*+A:ID58WAYAQ!^$5]%*+U-%G3N:-3T3C+J:-$\:?.;6/&A8^
M,5Z,A8/:N\^.-/;B/&#4X$X&>8CPU& X6'-;W<8Q\8I@.%GU4'D* PI*5;QN
MW'MJ24VAPLBZPYLR2XVPX\N[6 $!=OD**EH3_ N'$I(\!V5CU+>,^AFMYGR_
M;7J;2^W4^I?]2_#)7Y6S39\XV9B^61_G0WA@I)V.-N)\YM8[%#MJJG!P>#.0
MWME5M*KI55A)>WI70="XV^+=8,FVSFP[#E-J9>0>U*QA[_@J:=25.2E%Z45=
M6E&K!PFL8R6#(@7&W2<L9H=M2B>?;)J&VG"-JDI6.!8[=HP-=2IU%7H*>R43
MA56C*SNOM[:<UATK'0R9*3BD$[R,:Y2=Z1FH)"@"@$)J]J#%TNTVS+GN2056
MB&M<)M6T.3'?HHZ,,1B%.*3B/!MH"D:?/EW2=*N<]U3\Z:ZY(DO+.*ENNJ*U
M*).\DF@)6] &FGULU6DYXGL<RT9,C\YE2DA2#<I84VP-O:E(<<!["D4!:/0!
M0!0";SOE.VY[R??,F75(5 O<-Z$Z=_ 74$)6.]"L%I[P* HYS%8;AE>_W3+=
MV;+-SM,IZ#,;(P(=CN%M7PB@'ZZ)M33IYK=;+=,>Y=CS>GU%-!)X1(>4#$7@
M#AB'@EO$[DK50%N% 5V^T T/N35[9ULR_%6_:IK34/-"6QQ&/(9'+9D* W(6
M@);)[%)&/G4)(*;CL]RA!(_3'K9UITWMT>R/RHV:+'%"41X]Y2MU]II P"$2
M&UI<P & X^+#LH!XXWM++H$?GFGD=;F&U35R6@8^)4=7QT![_P"Y=(__ )VC
M_-#_ /+4 [G3KU?O:]9ZDY-7E)-C3'M[MQ],3-,DDLN-HX.#DMX8\S?C0$J*
M @+[2[^:Z=?E+K\46@*^Z O-TG_1;DG_  *V?U1N@%C0!0"9SSDZR:@Y1O&2
MLQL\ZSWJ,N)(X0.-!4/(=1CC@MM0"TGL(% 4SZPZ19JT7SI-RAF>.H)0I3EK
MN021'FQ"?(>:5N.(V*3CBE6(.Z@$[D_.69L@YAAYIRC<7;5?8*BIB4P<#@=B
MD*!Q"D*&Q25# ]M 3:R'[2"0S$:B:DY1]*E(3@Y<[(\&N8H=ICO; 3V\+N'=
M0"\7[1W24-\;>6LP*=^041$CW_2#\5 ,OJG[0C/&9X,FSZ<6=&4HKX*%W9UW
MTNXA!V8MX)2VT<.W!1'810$.'WWY3[DF4ZIZ2\I3CSSBBM:UK.*E*4K:23O)
MH"2W2%TW7'5[-D?-N8H:FM-;"^EV6\Z"E%PE-$*3%:^4G' O$;D[-ZA0%K_+
M1P<OA3R\.#@P\GAW<.% #K3;[:V7D!;3B2AQ!VA25# @^.O$HJ2:>IGN,G%I
MK0T1NSAEN5D^_%AI2T1E*Y]ME))2>#'' *'V2#L/OUQG-+"=C<<*QPUP?XVH
MZ]EE]&]H8O#'5)?C8Q19=U=N]N"(U\:]911@.>G!$E([^Q6SPX'OJXL>9ZU+
M"-9?<CO^;\_QI*F]Y;HU?-2? ]WR_E^- YMES[E6^!*8L]#,A6&,:3]"X"KL
M'%L)^:36[6F=6EQZ9I/=+0_QU&FW63W5OZH-K>M*_'6*8$$8C:*NRF"@,$ [
MQCXZ \G(L9W\:RVOYZ0?C%3B>U.2U,TUV"Q.;7+7$5C\J.T?C34\3/LKJLM4
MY=[/-65\M+&"[-!4/ 8S7X-.)[STKRNOGE^IFA*T_P CS&U-R,NV]25;RF,V
MA7WR #\->E4DMK,B&:7<'BJL_P!3$A=^GW3FXH_,XK]J>V_20WE8$GPI=XQA
MXL*^T;J:VXEU0YJOJ;\TE-?U+PP&?SEH%FS+33D^RN"_VQL<3B6D<N8A(VD\
MK$A0'VIQ[JS*=U&6AZ#<\OYHMKEJ-1?:ETZ8]^SM&H!Q]PX$'801V&LLW *@
M@=;I^S0_9,[)L2W/_IE]0IM;9/DIDM)*FUCO.!16-=0QACM1J/-5DJUI]W#S
M4O\ E>M?$EK50<>(]9_L9GZTVV&TGC-P,1YT?:,[%GW$IQK><OK\&72D_EXE
MWG,,WM?N9U3BOGX6^J)(6M&.GA0!0!0$1>MW)^L6IUIR]D73?+<BZV!#J[I>
MYC;L=M"I#8+<=KZ5Q"O)!<4K9AM3X*$D+3T>]1X&/U$DGN])A_R]""Q/I-TB
MG:.:0P;1?HWHF;+M(=N5]9Q0M3;KAY;316V2#P-(1]EYQ- /S0!0!0!0%=_5
MYTK:BYJU9>SIICEU=WMF8(S3]T##K#7)N#0Y3F*77$'RTI0O$?9$T P[/2'U
M*QG42(^1Y;;[*@XVXB3#2I*T'%)!Y^P@C90%KVG]PS+=<D6&?G.WKM.;783(
MO<!PH)1,0G@=(*%*3PJ4"I.!W&A)W)<.+<8C\&<PW+A24*9DQGTAUEUM8P4E
M:% A0(Q&!&!% 0HU?]GK9+[-?O>D-V;L#KRN)>7[D''( 63MY+Z MQM/VJD+
M[B!LH".-VZ'.HZVS'(T;+3%T92<$RX5PAAI8\(#[K2_?2*$'*=Z-NI%KSLC/
M'YDN"O\ <R#0'G^IYU'_ /@DG_XF'_+T!([HKT$U=TQU8G7_ #SEEZT69VSR
M(J);CT=Q)?6\RI*,&G%G:$J[*$D_J$$.NNG2'4?59C)*-/["[>E6M=P,_E.,
MM\H/ACED\U:,>+@5NH20W/1[U( 8_422>X28?\O0@MBT[MLZS9 RK:;DRJ/<
M[?:(,69')!*'V(Z$+22G$'A4",=U *N@"@"@$;J'IKDK53+SN6<\VENYVU7E
M,J5BB0PX?WQAU."VU;-Z3MW'$4!!?4?V<^9H3S\[2W,,>Z0#QK:M-X_-9B4[
MTMI?;2IIPG=BI+8H"/N8.E;J#RUPFX9"N3R%;E6\-W$>[Z(MW#W: 3:=#]9E
MJX$Z>YCXMV'JF9_)4 M,M]('41F;DN1\E28$9U809%T=8@A 5]DIMY:7>$?:
MH- 2?TG]G?:[7*9NVKU[3>%-*"AE^S\QJ*HI5LYLE80XM) VI0A!^VH";EHM
M%KL%MBV:R0V;?:8389B08R TRTVG<E"4@ >'=0'1H H#AYIRU"S3:G+;,\A8
M\N-( Q4TZ-RAX1X1VBJS,<OIWE%TY:]CW,LLOOYVE53CVK>B.=ZLMQR_<'+9
M=&N7(1M0L;4.([%H/:#7'+NTJVM1TZBP:]O2CKEK=4[FFJE-XKW=#.<0#OK#
M,LZ5OO\ ?;2 +;<9$9"3B&T.*Y>/>D[#6;0O;BA_;G*/;H,.M9T*WKA&79I[
MQ21-5LYQCB[)9E#Y+S*1_%\)JYI\R7T-<E+K7A@5%3EVSGJBX]3\3HHUGS(#
M])!A*\0<'_.:S%S9<[80]OB8;Y7MMDI>SP/8ZU7OA %MC<7AXEX>]C7T_P#K
M*_T1]IX_^6H?7+V'BO6?,I/D0H0'>'3_ ,]?-\UW6R$/;XGM<KVVV4O9X'FG
M63-0.)C0E#P<#GX=>%S5=_3#N?B>WRQ:[Y]Z\#J6[6N0DI3=[6E:<?*=BK*2
M!W(7CC]\*SJ'-LM56G^E_!^)A5^58_QS_4OBO <?+^:;-F>.7[3(XUHPYT=8
MX76\?E)_9&(K<K',:%Y'&D^M;5V&HWN7UK26%1=3V,[=696D;.H;($*V*8SQ
M:60RF6\(]W90,$EU8)0\!V$X$*]RK*UJM^5]AT_E/-)U,;:H\>%8PZML? 8>
ML\Z *_2J&].U'RXPP,5HE!]7S& 5K^ 5\:[PILIL\J*%A5;^G#O)N52'"1!V
MVP*G:EW?-<I/T%O89MMMQW%Q2 MY8\7%P^_5S4N."SA16N3<I? UZE9N>8SN
M):H14(^^3]R[Q>53&PA0!0!0&"I(V$@'O- 9H#'$G'#$8^"@,T!CC2#@5#'Q
MT <2<,<1AX: R"#M&T4!@J2G>0/'0 2 ,20!0&.-'RA[] ?5 % ?*G$)(2I0
M"CN!(!H#ZH H#YXT?*'OT!D*2=Q!\5 9H#'&D;U#WZ "I(&)( - 9!!VC:*
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MFU=KW&RC!<XXMG)>GJ2<09:Q@$?<)^$X5:6M/!<3VG5N4LN=*D[B2TU-$?\
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M2'T27R]+!0](?<;*D;4J4E*0HD\1)PP&(":UGZ-M3K#J2]J?T_24XR9:KBS
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% 4!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tb_product-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_product-4c.jpg
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M%!04%!04%!04%/_  !$( LX$ 0,!$0 "$0$#$0'_Q #2  $  @,! 0$!
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M.Y3*-O[!KV_^/.EFX^O]AYSBRK<MK3WHZ7]T;:?].6[;_P NN3Z_B?R]A?\
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@/Q]]L#_?.#_\ D'_Q:5>V_P ?_P!FY^G0
MSSO%?]VW[?VH_8->)/1"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH#\?;B?_ +7N.?U$1_X#U[7"?]7/V2.#?_YD/TTC[6W_ +D81_3D_P <2G ?
M]BY[?V#B7^Y;]O[3]@UXH[PH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% ?C_[3/_OQM]_Y,?\ _K0]>WX)_P *[_[?_)YCB?\ R;7X?_2/GVMO_<C"
M/Z<G^.)6/ ?]BY[?V%GB7^Y;]O[3]@UXH[PH!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * _'^/?\ [:;_ /\ ->?_ *K"O;WO^H7X?_1YBU_V4OT_
MAB?L"O$'IQ0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% ?C[[8'^^<'_\ (/\
MXM*O;?X__LW/TZ&>=XK_ +MOV_M1^P:\2>B% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0'X^W$__ &O<<_J(C_P'KVN$_P"KG[)'!O\ _,A^FD?:
MV_\ <C"/Z<G^.)3@/^Q<]O[!Q+_<M^W]I^P:\4=X4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@/Q_]IG_WXV^_\F/_ /UH>O;\$_X5W_V_^3S'$_\
MDVOP_P#I'S[6W_N1A'].3_'$K'@/^Q<]O["SQ+_<M^W]I^P:\4=X4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% ?C_'O_ -M-_P#^:\__ %6%>WO?
M]0OP_P#H\Q:_[*7Z?PQ/V!7B#TXH!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M H!0"@% * 4 H!0"@% * 4!P9CLW,Q7V@S;J.95@$2_5<@VCKJ@\,*C$4;
MDT"(:=0^=]&O0SXG"6"6'HZJF7HSU.5'!-8EWJY^ZG[#O->>.J* 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!7\0_\ 0OO]3D/\4I4L%@J
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@*_E']_CW^K)?R%ZE$%
M@J"10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!J2G^6/?_(5_P#
M- :N+_[:AOZ%K_)+0$K0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H"ON/\ >S#_ $QW_/;U(+!4 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M.D@&$ U&'R!?I&@.:Q6\['),?:Y%BN-S,PU6G3XZZ0112*LV,B<2*NE2BJ(
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MF,0H*J?1 1,0Q;7OJ"W30$_ ST/E$0UG\?>)OX=\45&CQ&XIJ$ PE$2W /*
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M754*1(RVH!.&@OTM0] $H21#C!<9>?9ZW&W(<@N?,(3)G80LEZVL LM$DW
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MSB!0"XVXC0&PFH14A54C =,X 8ARB E,40N @(=(#0'J@% :DI_ECW_R%?\
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M!^G]&A*SGZ S_P!=PK8+(SPD^_D7\7!NUF60/'!7+]0X$,H54RQ"E*80O8!
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MR"CVT9&I?W3-DBFW0+_\I$P*4/R4!O4 H!0"@*_B'_H7W^IR'^*4J6"P5 %
M* 4!^=MQLA@,8^U!@<KDDHTB(M/'),AWK]=-L@!E%# 4HG5,4H"(]'&I!!;W
M9DMEF<;?PV.2K25VZF&TDY-ZO/GA(Z3?L_U?(/),RJF_4_2!(HAJ,/'R4!72
MY?*-MI$<:R+)W,NH]S0<?A3XW,A<[8J952QCZ:=I)""91-I.X2 3&+I MPU!
M0$ TSW-,:P3?]GBD@=$F-'@O8K9G++9"2,+)',B_]6?K "I](%&XV#E' ?*
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M^=81 H<=N+G!MHWNG(GQ58C<Y"!8.TY$SU<(JY!!L9\32+E,-0V4'Z8<>BP
M!/92&2Y-E7VAE%LSR"-8X&S;RD!&QD@HU;D=>S5EP$^GSM &1_NRF HZA$?.
M H@).JN)V1R7[);V?FEA<RC_  9RN^<C8#*K&C3ZSC8 "YA\X;!TU *5]GTF
M4/<9P^/E,HQ(<<<PI&Z,;&$Y&2I@HT$J8 L"G!=,1N<P%OP'R\:DAG*6FW[
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M(%"= Z0,:PVO<;]/&@))/!\22Q,<%3B4"X@*)FHQ%A]7Y!S"8Q+7O81$1Z:
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M&54'\9CG,8PCTB(C0&B?",25CYN*5AVRD;DBRCJ=:J)@=-VNL0A#J*%->YA
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M * 4 H!0"@% * 4 H!0"@% :DI_ECW_R%?\ P#0&KC'^VH;^A:_R2T8)6@%
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M#XWV&RZ,ALNVWBO5DMO,ZC"NU'!UQ4=1.1 @0JH7. G<-E3I$'Z=R]   7U
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M=RF70ZG4X?QC#XZ4HVFZQI6J:S^WV%JKFG9% * K[C_>S#_3'?\ /;U(+!4
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5^=_SS&?ZM?_!K5(+!
M4 4 H"L;B9<VP3")S*W)BE]FM3J(%-:QW!O,1)Q$/I*&*6K>$P[OWHVUTOW=
M/N--ZYY<'+1^OH7XGXZ3PS=];9!73CK(T NN.:&G!<VE!5 G,YP)ZN/ZKH+I
MO;\->V>(PJQGSO6_VZ4^'V=IY_4O?:ZU%7YNO_S0N>YNX<3D3+8;/Y!T1!F:
M0,[E5OI D=JHU*Z'22X^:8AN !5'!825MXFTEEI1?C6A:Q-U2\J3TY?=4[M%
M[M;>9\TF8O$9Q.3?M8]=TNB1)=,2H@71JNJF0!\XP!P&O/3P-^PXRN1HFTN@
MZD;T)U46<F^SQ"KY-]FW(,?9G KN24E6B WL *JH%*0!'R!<0O\ @KL\6NJW
MCXS>9:K]YS<!;<L)J9FTU[C[LAO7@^#;>HX1GKLV.Y-BZCEJ[8.T5>8I=914
M!(!2#YWGZ1+TW#Y!IQ/AUV_?\VTM>,Z.IE@L1&%O4GDE#.>=E(W-,D)N=N7B
MY20;K,'P&Q9633$Z D364.=4Y"@(F#2?0!@"VK5\E.)3M6_)LS^+RU\5/8,%
M&4G.ZLFN\GL1?O%N:;3XU-93O7-QTHQ(*"4.A#-CI+'<&!34D('*4!$_FZ;\
M  !$1KG?;VL5<C##Q<7TZSZ"Y*Z[,'*YE2T',-O<UQ#<#<6,W$W'RA@GD G!
MEA>&-A54(Q%P<4R"L?1I,N<1^7I$!X>:4O5Q>'N8>P[-F#U<\YZ::.K]/;4L
M25V:N3?\JT5_3],E(+'<O@]JX[>O#,P6]3R!ZX>*134R9]3TKU)5-(4QM82C
MK(;B/T37^6K-ZQ/%2P]RWEBDJ]5*%>W<5F-V,L]6_;7,=3P:?#9O[-47.9$3
MD/FK)5=JQ7\PZCEZLHJV1TB(#<VLHF#I +CY*Y&*M?>8]QAF;S]265EVP_)P
MR;ST_66#[/V&/L:PH9W(!%3,,O6-.3:ZG]YJ<W,DF;C^:4VH0\AC&"JW%<0K
MEW5A\EOX5^!NPEMQA5_-+*SK%<<N"@% * 4 H!0"@% * 4 H#\=YO_OG(/ZI
M7^<I7T?@W_$C[9'QS_)/^QG_ "P_:1\?%RDNN9K$,5Y!T0O,.@V)S#E3O;4(
M?)<;5U+EV%M5G)176<2U9NWI:MJ#F\](YZ:20-A>:IE,=3&Y$B90$QC&0$
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MY,DXQ70NMTH2JN/*R\(1:0QMOBD\ZDF+""30(LW!V#D^E<JB"IS")4@L83@
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M,,E635HNHBFPCR+Z0,1))$0 P 4!*4]K_@N(C56W@)+4UM3X))MJNM*FEO\
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M\#B5A\2KTDYZKF^MRE6C?;677F(DASJG:C)JK/$DE$SK%.J901*4P"IH!01
M#& ! *M-)5U4HUKT=F8HI.6KYCE.C3=9-YFJTKDJ^@L3C*BKS&6S?(.5WD3=
MPT8<0_Z8CDY -K$!\B28$\V_'\%4(X2ENU;KDMM-]=-'XNIU)X[6O8B[1ZU^
M,HQ_+K4S_P#K%+)7+4@Y 8U4Y"Q*+AJAR"$7!PH"IQ<@ @H<@EZ"#PTE\E7+
M>NOG:;KT:.A/KTG/O*W)TM*48ZJ65U>MTM:%FHBR1N18M%R##)6L4[0R./2
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M+]M/\U*@>$4^^I?MI_FI4#PBGWU+]M/\U*@>$4^^I?MI_FI4#PBGWU+]M/\
M-2H'A%/OJ7[:?YJ5 \(I]]2_;3_-2H'A%/OJ7[:?YJ5 \(I]]2_;3_-2H'A%
M/OJ7[:?YJ5 \(I]]2_;3_-2H'A%/OJ7[:?YJ5 \(I]]2_;3_ #4J!X13[ZE^
MVG^:E0/"*??4OVT_S4J!X13[ZE^VG^:E0/"*??4OVT_S4J!X13[ZE^VG^:E0
M/"*??4OVT_S4J"$R#&2(+P@>UI13FR2:=SO#F$MT5AU%N' >'30$WX13[ZE^
MVG^:E0/"*??4OVT_S4J!X13[ZE^VG^:E0/"*??4OVT_S4J!X13[ZE^VG^:E0
M/"*??4OVT_S4J!X13[ZE^VG^:E0/"*??4OVT_P U*@>$4^^I?MI_FI4#PBGW
MU+]M/\U*@>$4^^I?MI_FI4#PBGWU+]M/\U*@>$4^^I?MI_FI4#PBGWU+]M/\
MU*@>$4^^I?MI_FI4#PBGWU+]M/\ -2H'A%/OJ7[:?YJ5 \(I]]2_;3_-2H'A
M%/OJ7[:?YJ5 \(I]]2_;3_-2H'A%/OJ7[:?YJ5 \(I]]2_;3_-2H'A%/OJ7[
M:?YJ5 \(I]]2_;3_ #4J#6D,4338.E/;$L;0BH;29Z<0&Q1X#PI4&MCV+$7@
M(I;VO*I\QFW/H3>'*0NI(HV* !P /)2H)+PBGWU+]M/\U*@>$4^^I?MI_FI4
M#PBGWU+]M/\ -2H'A%/OJ7[:?YJ5 \(I]]2_;3_-2H'A%/OJ7[:?YJ5 \(I]
M]2_;3_-2H'A%/OJ7[:?YJ5 \(I]]2_;3_-2H'A%/OJ7[:?YJ5 \(I]]2_;3_
M #4J!X13[ZE^VG^:E0/"*??4OVT_S4J!X13[ZE^VG^:E0/"*??4OVT_S4J!X
M13[ZE^VG^:E0/"*??4OVT_S4J!X13[ZE^VG^:E0/"*??4OVT_P U*@>$4^^I
M?MI_FI4#PBGWU+]M/\U*@>$4^^I?MI_FI4#PBGWU+]M/\U*@>$4^^I?MI_FI
M4$*MC) RMFU]K2@ZH]RIS1>'Y@:5D T@-N@;\0_%\E 37A%/OJ7[:?YJ5 \(
MI]]2_;3_ #4J!X13[ZE^VG^:E0/"*??4OVT_S4J!X13[ZE^VG^:E0/"*??4O
MVT_S4J!X13[ZE^VG^:E0/"*??4OVT_S4J!X13[ZE^VG^:E0/"*??4OVT_P U
M*@>$4^^I?MI_FI4#PBGWU+]M/\U*@>$4^^I?MI_FI4#PBGWU+]M/\U*@>$4^
M^I?MI_FI4#PBGWU+]M/\U*@>$4^^I?MI_FI4#PBGWU+]M/\ -2H'A%/OJ7[:
M?YJ5 \(I]]2_;3_-2H'A%/OJ7[:?YJ5 \(I]]2_;3_-2H'A%/OJ7[:?YJ5 \
M(I]]2_;3_-2H(UU"$C,AQQ4)!\[$[I<NAVY,LF'_ $BPW HAT_AH"Z5!(H!0
M"@/RTXWKS,F[IIDCP/@VA/DQ!9/2F*7K9D! 5N8!-=@4 5+ZK:>%>N7#;7VN
MK3_6U=?\*YOV'$>*N>?6J\NNKUU_3W'0-ZLQR;&,QVOC8&0,R8SLR+261*1,
MX+H<QL70(G*(AP.;Z-NFN;PW#V[MJ\Y*KC&JZLY;Q5V4)P2?S/*6;=*#S^68
MM7."Y67&/9Y'*TB)FI'?K!=!13#SP'3ITFZ/EJK@;MB$FKL->M*9:4-V(A<D
MO@EJ_A4XULUDFZN1X[\5\GSD5,0ACO3RL$+) %%D62(G$ 5*4MA&X"%=SB-G
M#6[GD0M_'*E)5?2]!S,%._."O3G\.BB_6;F)+_: WEB5,]BLM;8;"N%E0@8=
M-H1P"B:)]&I50Q1,)1$IBZAU7$!'2 6K"^L%@Y>5*#N2_B=3.V\1B%KJ>HNA
M4K^LOFQFY>09LVGL<S5NDWS;$W?J,J*  5)8!$Y2J 4. #J3,!M/F] ATV#G
M<3P4++C.V_@FJHMX/$2N*49Y)1=&73<.7RJ$Q)^^PF)]M9. $3CV0B $UJ&
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MIRY<^N/O[ASC9W5S^CQ#[P\+W$_^NAUZ<N7/KC[^X<XV=U<_H\0^\/"]Q/\
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M#"!3<;!RS"/R7"J..IA\)"PVG.NLZ=&<M6$[E^5RE%2BZS]$UYDZ@H!0"@%
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MUJ+JT7#7:^GRVZ+VJ*&=56G2?:@D4 H!0'S475IN&H>@/+4T(JJTZ0!BB(E
M0$Q;:@\H7Z+TH%)-TT'VH)/ *I"?E@<HJ?HW"_Y*RU72I@KD6Z553W6)F* 4
M!\,8I;:A +C8+C:XCY*FA#DEG/M02* LFWG^_L:_K0_E*50XC_Q;G\O[4=7@
M_P#S[/\ -_\ F1^NZ^7GVX4 H!0"@% * 4 H!0%?<?[V8?Z8[_GMZD%@J *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M"P<8Y6\[>=G!XAQ&[CKBG<2BHJD8K-'3[6R JZ<X4 H!0"@% * 4 H!0"@%
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M;49RE;^)PDD^B63-)97THRN\O>2)) 'S5(YI-^R?.@2$4TP;QQ1*BT(7C8@
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MPF\78^X>B<1W+VH>(?#'<3W>7_>H>DIZIA-XNQ]P]$XCN7M0\0^&.XGN\O\
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M 5_)P$7&/V"__P!U2'^ O4H%@J * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@-24 1C'H!Q$4%;!_P#D&@-7&/\ ;4-_0M?Y):,$K0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H" 7 ?&K ;</9COCY/[]O4@GZ@"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H" G0'VWC0VX \7N/XV:U2
M"?J :[]BUDVBK%\GS6JP:54[F+< $!Z2B AQ#Y: @O &)=W?QE_25-2*#P!B
M7=W\9?TE*B@\ 8EW=_&7])2HH/ &)=W?QE_24J*#P!B7=W\9?TE*B@\ 8EW=
M_&7])2HH/ &)=W?QE_24J*#P!B7=W\9?TE*B@\ 8EW=_&7])2HH/ &)=W?QE
M_24J*#P!B7=W\9?TE*B@\ 8EW=_&7])2HH/ &)=W?QE_24J*#P!B7=W\9?TE
M*B@\ 8EW=_&7])2HH/ &)=W?QE_24J*#P!B7=W\9?TE*B@\ 8EW=_&7])2HH
M/ &)=W?QE_24J*#P!B7=W\9?TE*B@\ 8EW=_&7])2HH/ &)=W?QE_24J*#P!
MB7=W\9?TE*B@\ 8EW=_&7])2HH/ &)=W?QE_24J*$-C6%XP[9O#KL-1B/WJ1
M1!58/,3<'*4."GD +4;!,^ ,2[N_C+^DI44'@#$N[OXR_I*5%!X Q+N[^,OZ
M2E10> ,2[N_C+^DI44'@#$N[OXR_I*5%!X Q+N[^,OZ2E10> ,2[N_C+^DI4
M4'@#$N[OXR_I*5%!X Q+N[^,OZ2E10> ,2[N_C+^DI44'@#$N[OXR_I*5%!X
M Q+N[^,OZ2E10> ,2[N_C+^DI44'@#$N[OXR_I*5%!X Q+N[^,OZ2E10> ,2
M[N_C+^DI44'@#$N[OXR_I*5%!X Q+N[^,OZ2E10> ,2[N_C+^DI44'@#$N[O
MXR_I*5%!X Q+N[^,OZ2E10> ,2[N_C+^DI44'@#$N[OXR_I*5%!X Q+N[^,O
MZ2E10A<@PK&&RT(5%AI!>1315#FK#<AD51$.)^'$ I4$UX Q+N[^,OZ2E10>
M ,2[N_C+^DI44'@#$N[OXR_I*5%!X Q+N[^,OZ2E10> ,2[N_C+^DI44'@#$
MN[OXR_I*5%!X Q+N[^,OZ2E10> ,2[N_C+^DI44'@#$N[OXR_I*5%!X Q+N[
M^,OZ2E10> ,2[N_C+^DI44'@#$N[OXR_I*5%!X Q+N[^,OZ2E10> ,2[N_C+
M^DI44'@#$N[OXR_I*5%!X Q+N[^,OZ2E10> ,2[N_C+^DI44'@#$N[OXR_I*
M5%!X Q+N[^,OZ2E10> ,2[N_C+^DI44'@#$N[OXR_I*5%!X Q+N[^,OZ2E10
M> ,2[N_C+^DI44'@#$N[OXR_I*5%#7D,$Q1)@Z5)'V.1%0Q1YR_2!1$/_J4J
M*&MC^#XLY@8IPLPU++,VZBAN<L%S'2*(C8#VZ1I44)'P!B7=W\9?TE*B@\ 8
MEW=_&7])2HH/ &)=W?QE_24J*#P!B7=W\9?TE*B@\ 8EW=_&7])2HH/ &)=W
M?QE_24J*#P!B7=W\9?TE*B@\ 8EW=_&7])2HH/ &)=W?QE_24J*#P!B7=W\9
M?TE*B@\ 8EW=_&7])2HH/ &)=W?QE_24J*#P!B7=W\9?TE*B@\ 8EW=_&7])
M2HH/ &)=W?QE_24J*#P!B7=W\9?TE*B@\ 8EW=_&7])2HH/ &)=W?QE_24J*
M#P!B7=W\9?TE*B@\ 8EW=_&7])2HH/ &)=W?QE_24J*#P!B7=W\9?TE*B@\
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M8!%=BU7,#@M@O;2<H!?Y &U<F/&K#IK*44^EK(=Z?^,XR*>K*W-K/%-I^_\
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M3;S_ ']C7]:'\I2J'$?^+<_E_:CJ\'_Y]G^;_P#,C]=U\O/MPH!0"@% * 4
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M,CZ\1)%NB +)G;J@4RAE.D3'$PCY-(VM6&*L2L8:WB(SEK_#G>3*LU.KWFS
M8R&+QM[!3MP\KX\B67X9)-MZ6W7J9&0+EMC6TCV6"/:R<@PFE4&JKTG,*!P6
M*F10UK";3?4 7JQB(N_CU#6<5*";I[*T*N%FL'PF4U&-R4+K2ULN77HF]-,Y
MM8X1LRP,V: ]B(O)<@D5N=*2:.M!(O,4_4(D # 7Z B!?Q_@K7B6Y8KR-6<H
M6XKX8O*\BRLW</U;>!^Z<[=N[>G*LYK(LK^&*Z,V;VD7DZ^"*36*9 N=G(:E
M.7E242D<6:W*+YBP)Z0U !OI %Q$.'&U6,+'%*W=MJL=WK/XEU5]A2X@\"[U
MB_+5G5TNZB;C*BR2ITTE[7330L^2(J3\!/.8$87*<>,D*K)LU*1F_C2D*(ZR
M"0!UF((:@ V@1M;\%<[#-6;L%<U[4ZY6\L9^W17\3M8]/%8>Z[/EXBVU\*C\
M,H=::K5K.JZIIX/(0K[&8*,Q5_%1^0(V&:C99N43R!S6U65-YUC#Q*8FKI_!
M:MV/MW(7IRNQG*#^647\OX=770K<'Q%F>%M6\/.W"XJ:\9QRS?3ESY?J6M^P
MPX-$ AN/E[.3AD(XR<<*Y8THE<MDC&,00.B)B@&DU]0>:%KB%98^]7!VG&;E
M\5-;,W[?8:^#X=QXEB(SMJ'P)ZOS177'(LCSYEEJ0>,G0Q':@N;,6C=UDDF_
M!D1V\3!P#=$%#$ "E&WZ C^$3<:NXI/$8[R)-J$8UHLE70Y7#9+!<)6+A%2N
MW):M9*NJM;5_97VO*;N0MV$Q&;>9T#)!E+2\BV:R:38@$07 %1\X2<0Z4_R&
ML-:<-*5N>(P]7*,(R<:YUD_>6<=&%ZW@\9JJ,[ER$94R*671^'8Z%L6G$6V\
M X4WAHTL.\3*9\<6Y176.9KK PF'@ % @%TZ;=(^6N8K#EP_SW.6M%Y,N1?$
M=V6,U.+_ &L;<-22K)T^)O5?<E2AQ'(&3>-R*9C6A=+1F^<(MR#QTIE4'27\
M0!P"O7X>;G9A)YW%-GSS%6HVL1=MQ^6,Y)>S1^!'5O*XH!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@/"I^6D=3I$A1, ?B"LHJKH87):L6]".M.G;C&9
M3'F!LM;Q,' L&))2$*JJHY74T\]<AFQ4Q(<RO,TA<W17F(05^%R7E.<[DI:L
MJ*BZ%\5<E*'M;LY82[9A]S&W;LP@IVZMRD\\EJ4RN54LY$IG@%HK&XAQ$++)
MY1+O)1M'MW'JH-T';D&B(B)"F$QB$ =)>!;7O5IJZIW)J:7E0C%MJM6HZS[7
M^)2C+#.S9MRMMK$79W%%2U=52EJ1>3I4<RS4K4C&F.1K<99=PV/)MF\FK&QB
MCIX2(:*HH&$IE.=?6HK?2700ND.D?DK?/$S>JD]5N*E*D==IOHIF2Z:LJV<#
M;7F.2<U&XX1UI^5%I=.MGE*OPT63I-@N,8\WRC(X#5Z\\CE$DH.,=O/9Y7(F
ML*Q!<@  91*^DI;EU=-8/%778MW/E4JZTE'6IH^'0_QH9QP.'CB[UAO7<**W
M"4]36KEDM?IE',EDKG=3XSQ6*44FY Z"Q8^/=(Q[&(E79(Q;UM5/FK$77O<0
M1 !TZ/./TU,\7-*$:K6DG)RC'75*T5%^;IKF)L\.M2E=FT]2$E",)S\MZS59
M*4NG5Z*99>\@,HCHV-D_5XAP51FLU0<B!%BNP;+*E'F(<\H "G+,' WE >-7
M<+<G.%9K*FUFI5+,Z=%3EX^Q;M7=6W+X7&,OFUM5NM8ZW\6K3/UEHBL@D6<.
M=_-E2C\$]GJL(W'B%*)9)P*0D!0A#!K-I/\ K57)AL \ $:YUW#PE<U85E>U
ME*4_H5<VC-D43KX?&W+=G7NI0PVHXQMY/]1TSJJJ_JE-^_*S*DT@W!L&P.59
M.'#U9FF95T@YY(-5I<QG&L" 4>8<  HGUC;2 !6+G=7GXB$DDI9FJZRAD_!:
M*&R-O#R^UP=R$G)PSJ5-1W*RK3^)Y,M<A6\-C&3_ ";U:4(5ZPC4GSU='H(Y
M]G$,8I;<?-.8"B(?)PJ_C;LH6:P^%R<4NK6[CD\,P\+V)U+E)Q@IR:Z)>7F_
M!NCI^!,X9E&39'ED:QE7ZCV)E1.23BE1#U#U+E&,H (_0(5, \T0M;Y:JXW"
MV;%B4H1490^67\6M7)ESNI?X7C\3BL5;C<FYPNUUX/Y-35;?PYDD:T?#XP@W
MQ9)XQ=R<CDKA4$DR.S-2)LC._5D%+%*(B>P:K< 'RUG<O7F[KC)1C:2_AK\6
MKK->S]$:K.&PL8V%*$IROR=/C<:0U]6+R=-,O1TU,K##F*IESIMWD\@,XO")
M R5!J#=LW$/^I7/I-8QBC<H&L2P"(CY*QN8V2IEC;?EJ>55JW_"E^C,['#(2
M;^&5Y>=*U\,M75C'^.32S]D:93!+,\8BVSR?58E>QIY!Q%P;!DX5;(*(1X75
M=JK>><QSW   + (\>BU9V9WKC5M2U9:JE)M)M.6:*61)(U8FWA;,97W#6AKR
MA;C"3BFH9YREE;;[.DS/\?;P/BE\R<N4V[.,8GCB%4$BX*3FG2V7$H?K  NO
M440\X  1K&WB'>\J,DJRG+6T?Z?\2T?L-M_!QPWW$HRE2%N&IE^*MW^&7U>Q
MY^G*;#K',40F)K%TFCHKR'BE7KF8,[$4TG;5N14Y2H:=)DQ.8"><-[CPK7#$
MWW;A=;5)S24=7.FVL^DV7,%A(WKN'49)VK;D[FNZ*48IND,U,JS^Q'R+Q>%;
M-V3R78N7C12'&<<3"JPH19%1(8R3300 %0-0%3.&L%#&'APJ;N+N2;C"23U]
M11I6?7+JTK)0C#8"Q&,9W82E%VO-<VVK:R9(46?0U76?L(G;LXJ9_C:@IE2$
M[[7R2!8A-2:@Z"AQX%Z JSQ)4PMQ9_A_:BEP5UQUATI66;H7PRR+J69'Z[KY
M>?<!0"@% * 4 H!0"@% 5]Q_O9A_ICO^>WJ06"H H!0"@% * 4 H!0"@% *
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MI]KT=5/:8HK.7#*$2QN7AV.0PK53G,$'X& [<PB(B!3% UR\1L%N <.BLKV
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M7GV\4 H!0"@% * 4 H!0%?<?[V8?Z8[_ )[>I!8*@"@% * 4 H!0"@% * 4
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M0#Q%C_>S/M"76H!XBQ_O9GVA+K4 \18_WLS[0EUJ >(L?[V9]H2ZU /$6/\
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M$4(R;%.0SA(# 8$B@(" FX"%""4\18_WLS[0EUJ@D>(L?[V9]H2ZU /$6/\
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MV'6]"C:A%XN_&Q*6:.1]K;_5DZR*F-OI>"R2(@'ZZ2C2<532CYAN F0.50P
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M*R_B:IJOZE+-DTUR>TE\JV\D<4B&\JL\1>B"B;>8;(6U,'"Q"J)D.(&&X#J
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M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5^=_SS&?ZM?\ P:U2"P5 % *
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M6;/Q_/)N4NXL<:QL,5B:VW6W;BHQZ^EO]2_ J5=,XHH!0"@% * 4 H!0"@%
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M+:NM.2RKI3:=-%5T&&'QM_#IQMRI%Y=5I2C731YG[#3?R#^5>*2$HY.[?*V
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M( C8+G_!3F*U]$NU=PY0Q&]CL/Q&..V(R"2CVDBG-,TR.T4W!2&05U%!4@'
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ME129[WAV$>%PT++==14J3M4SH"@% * 4 H!0"@% * 4 H!0"@*^X_P![,/\
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M1-101&P:"F$!-QX<*B-N4E5)M(-I&=RZ;,D#NGBR;=LD%U%EC FF4.BXF,(
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M>G\>?]YYIM5^XZ=;3_#FS:>@['O\NV?9OLF\;'*LV7G 605+Q*9,ZC,Q3!^
M0L-</A2<;6(3SZOB.AC76=K^;N.L;@X-B&8Q9E\IAV\JI%(.58\7 &'E&4(
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M% * 4 H!0"@% 5^=_P \QG^K7_P:U2"P5 % * J>Y<'D638/,X[BKA!G,2B
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M._YYC/\ 5K_X-:I!8*@"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MHXS)/&SC&B5M1@DLRU8]&C*V?H7:?_VYQW^D#_Q&KPW%_P#EW/:?3_\ '_\
MKK/\B+E7*.\* 4 H!0"@% * 4 H!0"@% * K[C_>S#_3'?\ /;U(+!4 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5^=_SS&?ZM?_!K5(+!4 4
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M2225$CF-N4G)NLGG;RM^UGBI(% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MP+]6E /%J'=4MV!?JTH!XM0[JENP+]6E /%J'=4MV!?JTH!XM0[JENP+]6E
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MC\&_XD?;(^.?Y)_V,_Y8?M/F(1K29RR%B) @J,7KGDN$RF$@F)RSFMJ#B'$
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MHB @!A&UP$!O66J]!%38171<I%7;J%61.%R*)F Q3!\H"%P&H:H2?061,J9
MJA17( &.D @)RE-?2(AT@ V&U* ^*KH(:.<J1/FG!-+68"ZCFZ"EOTB-NBE
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M=E=QN\Z]O)[<^\U"E H6 .D;B/E$1Z1$?*(UM;-*BEF/M02* 4 H!0"@% *
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MKEXC#W+$]2:HRS;NQN1UHNJ)"9F8O'HMW-S3I-E%,4Q6=.E1L0A"^4?*(CT
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M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * K\[_GF,_U:_\ @UJD%@J
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M^U1*6G-T&&M)VK:C\_17-GZ3I>T3F49[ZYHSW$*D3<J18-UD1C/\J-&H@F
MGJ_6<SZ']YY &N7CXQ>#MNS_ +:?3\U<I:PTI*]*-RFN\N3-3(?HRO,'6% *
M 4 H!0"@% * 4 H!0'X[SBXYQD :C 'K:O IC%_^JI\@A7T?@O\ Q(^V1\<_
MR55XC/*_EATOK(.UN(G/;_S#_/79/.:O6]I]Y\"P\ 4./_Z0WST_#W$))]+V
MGWGW2/Z9_KG^>E2=7K?:^\:1_3/]<_STJ-7K?:^\6'IUG_>'^>E1J];VGW@
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M7+#W,+#44E'65*Y:9:46GH=3RRPAYC.ZX0$21J^1.S5>1X3!3*H\@]BF*;0
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M_P!,K_\ *-91SFJ]\C/V?C/^W8K^D0_EA7R&?S,_0L/E7L)6L#,4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5]Q_O9A_ICO^>WJ06"H H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * K\[_GF,_U:_\ @UJD%@J * 4
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M='CFK+B>$>1TU?\ [1LOW3_XPSZ\!.M(V1,T0]62> "K1^ (%$4!-J*!1 0
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M.+Q^[*5Z$)3C.4(T>HJ*-:9,[T?@O:4:NP>=% * 4 H!0"@% * 4 H!0"@%
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M ! 0$+@/ 0'H$*@R:KD9X*BD00,4@ )?HC;H_%\E9.39K5N*=4CT8I3E$IP
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MR$[+'T$VJ9C<M"2=)-ECB! $"D30,H81'S0 ./"H! 36.-YG=>5EG>->VHK
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MO&H1Y4C-6ATTSD14%UKYXF,2Q=!A'0 " &WC.&K>WR.=PXDTZ;;?!(J-#UQ
M7B+F6<)K+OS-Q.407,!$$4]5A-Q^4: Z9LA"/<>VCPV*DB*)/TXMNJY;J@8I
MT%')>>9$2FXEY0GY8%_- MJ@%^H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!\,8I"F.<P%(4!$QA
M&P  =(B- :CF7BF:G)>/F[=82\SEJK$(;1^E8P@-N'30&5%ZS<M_7&[A)9I8
M1YZ9RF3L7I'4 B'"W&@/;=PW=H)NFJI%VRQ0.BLD8#IG(8+@8IBW 0'Y0H#Z
M*J0*E1$Y06, F*F(AJ$I; (@'38+A0'N@% * \'523.1,YRE.J(E3*80 3"
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M92IJ@8AG#TZQ7!Q4N"1!T:;\0 @)O(\^S2,@L,3R(64T&>NL:<2S)JF09!C
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M3YGN:;@2>#[B9Q$3B4/!PCM_CL)!@S3<"]4:J^S3JJKF,54JJSDQB(%2$H$
MI!-KN(4!J-L=FXW*,G6Q;($<:C]K\1BL83D5&B3[6HW:FDE0-SATE3 ID!6T
MAK/P\XNF@)A_NEE,]%X^[CY!:'4\.-)[*FT)&!*O&3J0; ND587=D$$ *50^
MDQA6/;\T.(B#;Q;--QMR#8Q#-))#&')\3CLIR.2;-4W:JCF8%0C5N@DYU$3)
M9%5541 QOHD 0XC0DK>>9M.QV1[8&F!CYO(8QH^D57L>H9. &2DSIP\:Z<KF
MN*+8W/6$QM)OUEB$N(@- =@FI>;P?;QQ(3LRT?Y4FERD'RS51)HM)NS\MND1
MJU!14Q14.1,B9-2AOEN-Z@')QW7SK&$<X+,.G<@$%B99QNK+Q:,4Y3EEUEFS
M9--% Q@,@N=,;%4N<HEMJ->I!,/\ZSS;B973R^:1R5)IALGE,RP29)L"-G$6
M9N1(K=0@F,8JYU%"65O]'4 AQ+0$?*QVX$CEFU$%F^0H2@3<@;))2);LDVR3
M-6":B[*5NJ0VLZ!'"J"8\[48PZ37#B% 77*LARU]N8EAF.2Z<)"Q<%[?R)\#
M1-XX'FN^4W12YGFD$Q4%]0B4W#H"]A "E8)N1NME$AB>0*Q[X(7)G0*/8MPQ
M:-8QK$.T%%FRK5Z*W/66( )'/<H@H!CV(0 "P&>$W>RI_ P*#MPB$U"H2LWN
M2_(@4I&\7!.'34$BICYJ:KU5#]7Q\U,BA@Z"T!"0^<9\9K!8G"-7,8JWQQA/
MY XQB$9N3%E\A,NN5$S=8Z:229=!U%#% 3*G$?.)81,!.FW9W!8KQ["79M4,
MDGL6C%8F&+H.F.3/GRC,X@HF<^IN4IDUU  QM"13#JH"6VQS_,<[DL?8F<H"
MTA8H[K.7J:)+.91PJHV:M4@O^I$H(*.E0M<"F2+P PT!I9)G.=/X[<C,L?G6
MT' [>*O&;&-69I.@D742U(Z<BZ4.;61-0Y^0F5$2F"VOSK@% 8\>CI'/M\WF
M42KPP,,0AX@&T"[:-UB-'TTD=VNFFH8!,19,$VYA6  /8VCZ/2!LY1FV;O";
MD9/ SS:!QK;GG-4&JC--X,B^9,$W[@7(J"4Y$[JD03*B8IA&YM0W M 51C.3
MV#8;#8C R[F/;XCC2#[*C1<6$L\;2SIN9ZH+Q1UI033L(JZ"CSCZKCH"PF$$
MFTFLLRK/\'GYC)!Q^/@\*2RW)F**2?J":LB9-,Y%#*&'S3II.1 Q[BD!+E^D
M-"38QK<?/'>:8<W>/EW3'+7;[4R/$^HQ01B+)9VFLQ<JB5T<Q-*("98EE-8V
M*3A0@_0%02* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M:-VHS&1CHR*DW**\P<48A5\Q=LVSM8HB44T5UDBIF/<+:=5Q'@'&@.JW 1$
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MEF.5$75C9:.0.ZCR)MTP5$SAP2Y$M0#I)K^D:X=(#0%F Q1$0 0$0Z0\H7H
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M!0$7(Y) Q,K%0<D_1;2\X99.(:*&LHY,V)S%03#RZ2C<: E: 4 H!0"@% *
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M# )F+PH\7O9MOE.X,&X7R22Q%LB_FRHKN4_%S?DIE%=5'40BA42&*)C6(/\
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M!FO![I9YGC[ H9]F"6%MGN%FRV2G2-V@D>R*3L6HH&!T7E@F0I164(33<+]
M6$ +)L0UB'?V2XAI,2BF/0KB-E"2$LW6(U4:H*/G7-5(J<#%(-A$=0APJ RJ
M[214"T>YEFFV$DTP3 PQKV; G?+I+G=+LCF,:?>-%%+IE+8"%YND3E'48H7L
M,@Z'O*W-/?9^+%RF5Q(KS"40DOD[TQVD0\.+A!8Y]34JO+3< 00+I\VQND*
MJ.U.2FV^?9WB4-@\7+3,&>)7<_#_ %$0=IR":HEUIOES:#H 7C^N'4!KV"U
M:DC([D2/VD4Y? HJ+99*\P!JJ_B\J472%J@>3/K3$S(%?UH'!.X .FWEO0D@
ML6QEODNWF_JFX<3%O9^(FIZ1 J!3+,VLF6+ 3*M3+% X6$.!C  \*$$BVQ?9
M;'OL_P"W\[F;4&K)VUBY)S 1O+2/D<N+0"(I."6 RXZCB?B<I2B.HP@6@(!W
M *8_@&W&.9J\0;[>R^9N%\HBF;X'<;%-G(&691*[I,XE%$AA_67-HOY; !J
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MS'$+F2$PW$@^;>@-#'=O<$Q%N]:XQCD=$MY&X/TVC5)(JY3 ("5327SBV$0
MH\ ^2@/6/;?X/B39ZSQG'8Z):R-_7T6;5)$BX& 0TJ 4H:BV$0 H\ H"OR.R
M^!&P_)<1QB'98PED[15F^>1C1))32J42WL4"W M_-+>P>2@)?#MN,/PA$#PD
M0R;RRS9!K)2J#5%NX>>KIE)J5%,H7U"748.B_'IH#Z?;+;M2$>8V;%8KP^_<
MB_>1A6:)6RCL0 HK"F!0+S+% -8!?A0&ZCA.'MV,3&-X)@E'P2Y7<,U(W3*D
MT<)@(%51*!;$.&HWG!QXC0&QD6,8YET?[)RB*:S$8"A5O4WR)'"/,)<"FT'
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M!L(\1#H$>- 2\-"Q./1C>&@F*$;$M"B5JR:IE113*8PF$"D*  %Q$1X4!Y)
MPJ<TKD:;! L^NW*R6DP3*#D[8AM94C*6U"0#<0+>UZ C)W;_  ;*)%O+Y)CD
M=+2C5,R#=V]:I.%"I' 0$ESE'S>(V >B_"@-EMA^*LETG32&9H.4(TD$BJF@
M0IR120W(T 0"X(E'B"?T: T'FVFWL@QB8Q]B\6YCH(=4,U5:(G2:<;V2*)1
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M5QXPH'*J9,IS@"JXID*.D>!J IN'[[;L,]K,7R*<B8[(\AR?*AQB* KH60K
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M"_2MT@-* HN6;NSLONOBA,9G6\?MRPR0,:DRE62!:5>>KJK.5! W$&S<R14
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ME );?O=.&+G;-WAL.,IMV5K(9 <DJMZLI&OT.>B1L(M@.=>P&U"8I2!I\HB
M4!DG-X5L;F=SLJCF+AT:"QV!EV[-Y(+&9G!^ B!2M@*)$3  ^<8E]8]- 2 [
M_P"08T_R9GN+C3:/4B<8)F<<E%/3/14:*+BU*V6.=),I5A4$ U$ 2](\0Z0)
M#:/>V8SS)E\9FXMF4QX\)5I*PBCQRQ3_ %@$.R<G=-F]G) ,!_U>HAB_)Y0*
MPVW=R7&=\MTX->#R7,X9H,%[+80*";U&-YK 5%=9554@3YYAU!IOJTC4$D?M
M_)[BYULRVGS91.,B-9>97FTHY!-YDSIHW7.5!FT%;61,Q!L!@TFZ+!PZ9(+M
MMEEN2SVQ,Q.R\N9Y.LT9E)!T<"(R38&@* @F^(F4I2/$P O- H<!MY: XOLS
MG&5265;9MV&:9._D9])9SE3#*@*2(700;ZE"QAUDB&5.4PZB\HYN 7$; - =
M)Q3[3CC*<JC4&<,V7Q2:E#0[1-HH\7FVP J=$CYVD#4&Y6QCD#5I7$Q .41O
MQI0%DPC=K/\ .GC#(HC#VZ^UTI(N8MM()/KRR";511 7J[<Y"I\D5$Q#0103
M@''CY0*WCOVFW619A'LF,,V<XK*S(P+9-JJ[6FT YIT"OW*7JP-RM14( &LO
MJ(!@$;TH#VT^T'FH-"95*8FR1P)ODJN*R+Y%^=1_J%V+1-TDAR=/+(:P* 93
M48?HA;C0&A'[X9_B3C=W(=Q&S%WBF$NDFS-I'JF]8*[<@@1LV3$4"ZDE.;J4
M54'40W "B7H GGF]^;8L7*X7.<:8-,PA,95S*,2CGBCEBX8HJ<DZ*ISI)F(J
MFI8#:0$IND/P@6W%LTW0EV.+24GA;1-GD2YE7QV4H57V7%G;)JH*K<U),555
M#B<!(EP*%N(B- <_WVR[<G&]T\04P-R=PU81$G-S&-"<P)2;1@=+GI$( #J7
MY1SBCPOJ +?((%&RC=Z:G,7WYRW#\H>C!LT,2<XFX05$@LB/DTA<@D'2F<QQ
M,58O3<!#@-"32W)W.WH;[?FQSUAU"9'MZLT+G&3H""19('3I)K' S5 1U^LI
MJBY6\T-.BWEM0@Z(M#99N%OIN3CZ&?9#C4?C3:$5AVL0X3*U*J_9B905454S
M@<-1-6D!+>X\: J<AO/E<_M)B^/2&4M<:S?(L@>8\ZS'F$8H R@U#'</B&$Q
M2E$X BD-A !,<;6X!0';MFL]6W"V?A\G76 \R#-1I*J$,4__ -P8ZD%CZB"(
M>>8G-+8>@P5 /R_%;V[C1.PLK'9A/+)Y+-Q7M[ <K*L)7+E)%Z1-ZS,J8 'G
MH6$0*%Q%,_X J22R;KYM*L-S<N;/\NS&*CX: CI"(:8L4R[8'2C<QE#NP%)0
MA$Q,4HB)A* \?.H077(G^XAMK,8S#)]QB8_&-X KAX[@"HKR$O/N"AZHFD/+
M.FHF<MO,1MK.(_F^<4"H9ME&Z"V0;=Q.3NLM:S#_ !-21G(?!>41\:335 "J
M*HJ!RP  &RH>0W .% =5V>SS<&<V]P%PZ9)99)O5W##-)=-P1BI%"W,?3SD%
M2%,HL0-*:I2E#SP$?* T!!;]97N7CVYF$!MZY.N#:.EI>3QL3F!*4;QXHF50
M A2FNJ*1C\KAP-:W&@/F ;X8_(9MN9F$KE(EVQ2:XNO"'=G'U=F>0:+ JF!"
M@/+4,J2RA>G6%0";G][L@?9:UQK:N*B\D9O\94RIM,/'RK1#E(/#-CA8J)Q.
M Z0*4 L.HW&Q0$:D&GA&_F4Y'*X&O.8PTBL3W!;OAB7"+XSEZBO%MS.%CKI\
MDA 2.!# F!3";H$UA\V@(O!_M,3&;348BS@V0Q.2'<(0Z*"SQ:18J$!0&RDH
M4&H($26,0+BBJ?1J"]^-* IP[H[S2&V/M^8<($E$L\9P\<,4Z]75=$*_51<,
M5C<DA"(\")IJ#J$X7$X<.(%^=;^YA M\L)D^-L$7^!S,*VRHS%XLX;$A9T@&
M!R@<R)#'51U%UE,0H6N/"U :.;[KY+-9)#-\?5&+QN.W-AL2%\T7-S9(H-E5
M9!%8MM/**IH3X".JP] A0$YO'O'C3C;K<".P+*D_'..LE55TF*AB.VAFSI)!
M4U[!;2<V@;#Y: @0-FNTV1[9O4LUF,K@,Y?(0\Q#9 =%VJFJ]0YI'+94B:9B
M%2$/.*-PM0%\F=^,/7Q.=G]OI.-R1[!^KE=IJOB1[1OZVJ*1%'#A8  "!I.;
M20#'/ITE"XU *4R^T?D3C#,QE4<<;3.08D]8M%5(91ZM&*-Y%,% =B!VP.BI
MH%U<XH(B/"Y> W"0;(?:&GSX-"Y)&PT1.R<KE3/$VY(N4$6+H'Q!,19,ZB0*
MH&U6(*;E(HEXFZ+4!(([WY3'Q>X##)8"-;YO@:D>#E).3*A#JMY@@*(+B[=D
M2$H$+K%0F@3#IL4-1K !74OM-3I<1R^3]B1TI/XE(PS$1C73@D8^2G3E!,45
M'2"2I#$N)3:T]-^("(4!+!G.^)-Z<2Q*58PC*)E(MR_DXML[5<%*BBX(110%
MC-B'%9(A@ A"V3.(C<0X4!@BOM$3K[.F6*K1L*9"<>/HN+18R2CUXT=-4U#H
M"^.BB9MI5Y?G%06.9,#<;B%J4!!XKOYG\!MK,Y=N"VCWSQ7)3XUCHH+'33]<
M.Y62.1R*;?S&[<"7(H0IU%"@-P W2!U79_=%]N*G-,Y5@BA(P:J!#24:+I2(
M?).DQ.4[15V@W4$2"4R:I1)YI@Z;"%0#\N,-P<S4=K.H[.<I3S=7,%H>/:R-
MAP_U4K[0"2RRR6@#"F @!2J:KV "\;U(.R9E]II[ YA.1$)"M9.)Q=XE'23(
M578S;Y8^@5ACT$6RB(@B![CSE2ZM(VM2@+)*;L[@OLKR6-V]P]MD,%ACEHRF
MN:^]5D7B[HA%5"L4S$Y7Z@A[FYRA=706@*[FWVEGV/9C.0D%#-)*-Q=P@TDF
MBBSL)A^LL0AU2QZ*#95(>2!_.YRI=5AMPXTH#=R??+/HZ7W 3QW%(]_CVW96
M;Z5?NGZC9==BY8E>G(BB")_UQ2B8?/,!0 +<3<* UVF[>>K[Q.DS P#:E+$4
M<L%(3&];)'*B=0'-@2$PN!$O+,B)^6! U .J@)+#M[\NEIG#!R?&&D9BNXZ;
ME3%'C1Z9R[0,@B+E,CY,R1"@*R87**)C:1X#^ "?V.W'S+=3%4\TG8)C!P3Y
M,?9 -WBCM=8Z*RJ2QU"F23!,ER ! U&,/$1MPJ <7QF:W"QG,XCXMY-E>-Y2
M\F>0J\522D\$DVZZQ@29MBI:0:G4()2D4-YQ1N)O(!9!T=WOU,-\2R?) @V_
M.@,X4PI)N*YQ*JW3=(MO6#"!?-./-'S0N'#IH"IFW9W*Q"6W9R!..)D6&8GD
M!/7?77YDG"# R*.M!@B"1BW3U\TW,.4O&P7&] 2J.Z.\!]P]R&T:QC)7',?A
M&TU"18JJ$6,FNBJLW HE1 QE7!2?K"G-I(:P%$;T!N3WVC73>(?3^.0R#^'C
M<-8Y<]757,'+>2RX)MF(Z &PZ"J',/X+4!O%WTR7')*:9[CXPWC"-L87S.*"
M+>B],=HU.":C-<RB20 X 3%\XET^/30'W:3?28SS)"8_-13),KY@,FR?0JKQ
MT@V$!*(LWIW+5 I5P*;4!DQ,0UAMY* KN]TANCCF1>T8#-3)Y'*O8]EMQ@$<
MB15-X0ARB_4DBG3$YB 43F,H4Y2)E /.N- 4#=;,L_1W0W7;P$QF(&QA&(<8
M^GCW+6A& KQY57)Y1-0IQ!(1**A=!1'@<:$GZ[Q63+-8S#RY'J$D#YDW<#(-
M+@W7,HD4QE$P$ $"F$;@ A</+4$$O0"@% * 4 H!0%4QW;Z%QB3RN5CUG)W&
M8/ D),JQRF(14$01LB!2%$I;!?SA-0')=P=@'$AMKBFRN&-R&Q)@]%R\R"3>
M#[08)@N94XH)II "IU2+KI=)2E 0#C>X2"_95LKC&32T;-MG\ICDE'1_L(5X
M!T#$SB'U ?U)4=!QY0&"X<L2G+Y# -K0!C&RF(XDYP]S%KOC&PEF_CX@JZQ#
ME,C)GUJBM9,NH0'Z.G3;RWH".<?9\PMSD"LJ=[*E@UY0N0N<1([ L&K+E."G
MK!T.7K&YP QD^9RQ'\V@-F/V*Q&,EV>3-74@&7-99S.+9"99,7KI1\4$UVRY
MN7I,V,0I2%2 H 4"AI$!N(@1&TFULQ 9_G6Y^4,&<5+Y4LFFPB6#@SQ-LV(!
M3+J&5,1.YW2I2JG*4M@$/R 2$=]G_#8QK'1S=_+&B(;(D,MAHY1T0Z#-ZW%4
MW*2NEJ! YUCG.03"(C^=0$?N]LP?*<>W">8J<Q\RS:/CHY1%XL4C(I(U8IB"
M6Q!$HB437N(W'Y*D$OC.Q^,0;F4D9)_+9#)2\4./G7FWGK:C6(4N)F;<Y2)F
M!,3#?4;4<>D37J 1Z/V><=:-L:289)D+1YB@.6\/)I/$?6TXYV!2F8ZS("')
M*4@%3$"@H4.@]2"2QS8K#,8/ABD<O('-@JTLXA>>X*IJ/.ZO6.>/+ 5+:QT#
MP$/*(U /2>Q^'I1"$*#A^+5OE 9LF85D]?M,%Q7 @CR[<G4/T;7_ .*I!]#8
M[#0TV6?^;F)MQ _7D_SDU[D_N_[CSA_5]/\ Q5 /DKL;ALN&2'=+R";O(Y5K
MD O4'!4G#"38)E3079'*3]6<FFX";5T_)PH"P81@K?"DGYO;,K/R<HJ5=]*3
M;GUE<XIETD*4I"II)D*7@!4TR_AO0%<6V)PUQM].;;JKOQA)Z15F'#@%B [1
M=K.2.]2*@)V*!3D"URCPO>]Z QS.Q./2\U(2Z<]/12,X9NKDD9%O_4VDDLU(
M4A%50(GS$SF @ H+=1/7Y:D'C)=@</R>>E)AQ(2[)AD"K=?)H!@\Y$9**M *
M"9G">@3@-BEU\I0FNWG7&H!FG]C<=G)^4FT9N<AF\^H@OD41$/Q:,I!5L4I"
M'4 I!53,)2E XH*)Z[>=>@*>[^SXYRO.]QI;*):1C,8RIS&"DTA7_(+(,F;,
MJ*J#U(4S !=9> D$#B43!JL-2#H3S:'%7.71V8MU'C!XQC @%X]JL!8][%%
MX$:N4#D.!R%$]PTB4> 7&U0")Q#83$\.F8R6;2<Q)HX^FNEB\7*/ <LXDKLH
MD5]5+RRFN)1T *ISZ2\ H"V8'@D-MUAL?@^/*N1B(PJQ&RKE0JCD <+*+F$3
M@4H7 R@Z?-X!:@*-AOV>H;!9DLS!YCE8BH\]I23-S(I*MY!R(:3&=AZL!U=5
M@O<] 8I#[-6$OG#YNE+ST?B$HY%]*86QD.3!N%SFUG$R()BH4IS6,8B:I2\
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M!<1J 1^,[&0.,KH\K(<@D(M@T7CH2'?R'-91[9TF*1RHD*F03Z2#H3YYE-
M%NBI!\6V(Q8V-X=CS&3E8U?!1../S3-=$K],%B"FJ!C'1.D8%"C8?U7#R6J
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M\+ %0#(3[/F(>I2;1S*3+U27F6&1/GCMV19R=]&:>7YYDOH&T^<6W#H+I
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M;KJBL?GJBW-J$1&W  X 'R7J 2D'LKB6-M,<90CJ49H8X^<2I 3?*7?.W?\
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M&(<#I'$O$ TF_#4 J6.?9TP_&'N.KL9B;588D]</\<B'#PAV+,7?,%1(I 2
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M@&;(MC\>GY^2G4)N<@R3HMS9%&0S[U-I(&:%*1(RMB"H0VDH$,*"B8F#Z5Z
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M-RQ:.91H9F5T10@'UH 81$Y"WTB</-$?HB(<:@%OH!0"@% * 4 H!0"@% *
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MRF E(H9JD5/44#<0 =/"H!9* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MF5XJ4RB3<3E!4Q"" &,4M[B 7"XT!FH!0&%9VU;J(I.%TTE7)N6W(H<I3*'
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M%$S =,P7*8H@("'X!"@/5 * \<Y(510!0O/ NL4[AKTB-KVZ;7H#W0"@% *
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M-8 *KC\WE\7L'+9%D[Z.RU+Q$5DT82L?SDB*>)_555%!564Y@>=K0+8.38H
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M30$K(BZ8E232*4")G*N(<OC;Y1$1&H!H8SL;C$%MU*[<2#QY-,)HQC2,D[.
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M!P)82#XC=BS.+=%80 BSMDBN=R@GQ\X3)B)/S@"@.M$.14A5$S =,X 8ARB
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M+KZ@02,8 .<2!J-I 1N-@XC:@*Z.X6)%S4^WYI)(N3D9IR MC& "\I98R)2
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MT H!0"@% * _'>Z4KC,DAO*].VQ^/E&8NHY0V0G4?Y*Y=LF1#-E8]$#$%J@
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M#JY*BR+H3'*;H%"PC0'V7B,)QC,&6#J,\<;DP_%F# )#-1,X0<LUCJZ_9T<
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MH#]BND$%2 HJF0ZB%U$#F* F(?2)=11'H&PB%PJ <P^S2(#L1@UN[@_^"IZ
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M2@/#>!@VB2Z#6,:((.0 KE))!,A%2A>P' I0 P<1Z: WA33%,4A( I"&D2"
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MY5F@^:"(&%!TD19/47H'2<!"X4!E;-6S)NFT9HIMVJ0:4D$2@FF0H>0I2@
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MHY(D0KA8"E56*4 .<"7T@8P!<;7&UZ $;-TUU7*:)".5@*"RQ2@!S@2^D#&
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M5PH7AP,H!0,(< Z1H"MX;MO!XB@N7223=J2DC+MGKI!(5VYY1P9PHFD>URE
MQAZ!XT!99*'B)E--&78-I!)(W,23=HIKE*<.&HH* ( /X: RO&+&1:J,9!LD
M[8J@!56RZ954C  @( 8A@$!XA\E $F#%!F$<BV23CRDY)6A$RE1!,0MH @!I
MTV\EJ ^-HZ/9\OU-HBWY*0-TN4F0FA$!N"9=(!8M^.D.% 9$6S=N*@MTB)"L
M<55A(4"ZU#  "8U@XF$ #B- :[6'B&+MR_9,&S9\\'4[=(HIIJK#>]U#E !,
M-_TAH#=H!0"@% * 4!RR:W>E47^1EQ/$'.2P6'J"WR.31>(-CE<I(E<+H-$%
M $7"B*1RB<!,GYPZ2B(U(/K_ 'D%Q-X]!X3CSC*%LGA2Y'&N4W"3)N1B*J1!
M.N98-28 54!^B8=5B:;C< (N/W2C8!EECA!M+2\J;-UL6C(IX[36,XE%DD#D
M2:G/I(W:@41/I,/F 4X\1&U 0F6[KSJ^/[@)Y+%.,>2Q$L4D\CH62TS@JR+A
M Z*Z+TI00*@H4QBVMK\PX&M<* N$SNMD*>7Y%A6(X4XR*5QM!D[>K^O-V+84
M7Z1U"% ZH&-S1$@E(338W$1,4* S$W:5F,;Q&<PO&GDXOF#<SULB<Y6;5DW1
M(4ZQGKL2J$2$IC@F4H 83F^CT"- 4W+=\,J5P<DYB$"#>=89.VQC(V;ITW,1
MJZ]:;IF234$HD6*N1<H$5+;0!M0AP$* N<GN9D:$O'XC#8@:3SE:-"9EXL9!
M%NTCVAE10)S'@IF YU#E,"9")\0*(C8 X@1SS?9BEC,%-Q^.OY"6F)U3$W&/
M)G0(]9S*)%Q405,<X)"!#H"43@?3I'7T<* ^R>\&0-)P<488;Z]E;&*;S,U$
MA*-D5"%<BI9!ES":GB@<H^H2%(0!T@)@$U 72;S-"&V^?[@*,'0-F$0K-GC'
M1!:/0(BW%P**A% NFJ !I,4WT35 *E$[P2*\GC)<BQ%U 8WF1B(8]+N'2"R@
MO%FXN4D'39/SD#*D(?E^>?B%C::D$-*;NN,@Q?<)WX=E8S%L42G&+_(6KY%J
MZ4>1!S)Z6.D#* )@*)N<8"@F;AYPWL!.NMS))%]%8EA>.N,GR(8=M-2!'+Y-
MDDU9.+IHBLY4(?6NJ8AK$*3CI$PB 6H#4>;ZLR8]CLQ%8X_DI6?EU\:- $.@
MB\:2[4B_-06%0X)@!#H"4Q]>D"^?T<* W-VLUS7$=GI/,8F*2;92T9 X<M3N
M$ETF)M&I0VLQ *ORQ\T"@4-5Z@'QWN?DC(F/P0XB9SN)/I.724 E(H"W19,A
M("CI=Z!!(4@BH0" 5,PB8UOE&I!8L#SE/-&TFBYCU8;(H%X:-G89P<BIV[D"
M%5*)5$_-4243.4Z:@6U /0 @(5 *E*;TOT%<CDX/$'4SA&'NEF.0SR;M!!4%
M6)0,]%HT4#4N5L B!QUDU&*8I-0A4@M,3N)&3>:^$(U$RZ!X!GD[:6*<.2JU
M?KJ(IE*40 UQ!/7?Y!J 5)SON@ECL5.,L:>R#F8R5WB+.,;*H\\SMH9T0%-2
M@D(!#&;#>Y@T@-QZ*D%ZD<G?06%+95-PKGVDT:>LNH",_P#N3H5[?^G1%,I>
M:83"!0&P!Y> 5 *S![J/C9*.*YSCWA:14C%YIHH5^A)(&;,S$*Y(J=$I1352
MYA#"%C%$+Z3C:I!IP.\,S,J0$JK@\@VP7*7";:$GRK)N5]+DIC-EW3)(HG00
M6 MRJ"<P%U%UZ;T!H3>^LC'QV393$X4\F,#Q=5XT>3B+MNDJLXCA%-<R+4X:
MC()J%$AEM?D,8"F * ND-G[>8S1QAA&*B3AO"L9XSL3E,F*<@HJF5("@%[E%
M(1$>BH!3#;H1^4(X', WE(\)3*GD&@V:/"HIF68 \1,+L"ELJ@;U<QN7\ND?
M)4@VH[>E[,3;U"&Q)U)8Q&31L>DI-FZ07D&SA-7U<[A6-( JE;E4Z3B;4"?Z
MS1IH"H[@;F9'B^,;GR^"INW,[ S[)BZ5EW9'#-H1=%J83M4#@ %2,"A4^4 W
MUG$]^%J NR67JDW"@VN4-7T%+K8[)R;R.)(D<1""#-VB0QU2$(4%%=)BF*H%
MM)1$M :<=O<\<)0612N(NHO;O)G3=G"Y&HZ146N_-H9JN690UHI+B)=)]9M.
MHNH"WX >)C>V::JYB:#P9W+1F".5D9^0]=;MDQ1;MDW1S-BG QE503.(BE8O
MD\ZY@"@+])YSCT3@ZNX;U<Q,:1C@EQ6 MU#-CI J0"EOQ.8! "EOTC:H!5H7
M=*:-D$'!YMB#C%BY2"H8\Z.[1>E4712%P+9T5(I1;K"D!C%+<Y1$HEU7#C(-
MK;W<F3W!>OSML7<1N-QZ[Z//-.G*(@L^CW0MQ300)<YDQ HF%4VD ,&D -TU
M *1,YG(-#;]*3,A(GA,8!@+!&-< T=MD5(A%PJ#5;2(IG,<PFU#?C4@MLCN7
M*(RK3$<)QM?*9]"+;2TH5=ZDQ1:M7-R( JX4*?6NJ)#B4@%Z $PB 4!A>;RE
M&+Q<T/CCQ;*<J*[.UQ^3.2).U3C# 1X=VJL!@3*F<2E*)2F%34 D 2\0 U'&
M_#1IC)Y=?'G9YUGD#7%)3'6RR"SA-^]$G+%!4# FL0Y52&3-<NJ]ATB V4!N
M,-X'#1WDT9G6-+X[+8W"^*#-6[I&4]9B0%8ICIF1 EE2G0,04S>6UC"'&H!Z
MQ#="8RTB!I'%7$9#R\8K)Q,Y'OD)5F8B92B9%==N4"MW&E0IB%'44UC:3")1
MJ05W'MWQ8XMMI'P,#+Y)(YO'/7$45\_14=E&.(DH(O7*NFX&!7SE0*-K?1$1
M * FF^]R!,<DWLQ .&.71<XCBA\83<(KG7EWO*]5(BY'EIBDJ"Q#<TX%TA>X
M<+"!)85G>4Y+FL]C4Y"-\?+C[1HJY9&<&>NU59 3F16363*5'D"5)4FG^\UE
MXV"UP-::W6F234]&8;B#C)VF*"1/(7J;Q%GH<'1*X%NT(H!A<*D2,4QBW( "
M(%U7H"D9CN)EF89CMI'8(1T&%9.S<SI7;!^W8.WR;8C<W+4YR2ADB(<ZZB?2
MH(Z0$-(T!;MW<ZSK$)S!V&)0Z4BUG)8&3SFND6YEA]6<*@V+S2F$@CRM?-Z
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M0,8!&@-)[O0#EUB;'#<<=Y$ZS.&4GH@ 719$302Y B#HRHCRPTK!<Q=8ZO-
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0'&5\-W.Q9YFD7@K>)?0>;/W$LA)2+I9NXBGC]!-%R)T2(*@X3 R?-2
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M<!, 6$! GO!.;X/FTC.[>-(V4ALCCXR/?MY5VLT58N(9,[=%P04D5063,D<
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * QN&[=VB=LZ2(NW5 2J(JE Y#%'I Q
M37 0H#$QCV$8W!I&M46;4HB)4&Z94DP$>D0*0 "@-F@% * 4 H!0'E1--9,R
M2I 42. E.0P 8IBCP$! >D!H#Z4I2% A  I"A8I0X  !T  4!]H!0"@% * 4
M H!0"@% * 4!Y43363,DL0JB1P$IR' #%$!Z0$!X#0'T  H 4H6*'  #H *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
C 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2531771d2_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2531771d2_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X )(# 2(  A$! Q$!_\0
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5<TA4G3NX-J_8UZ***9F%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Nov. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001999480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Alto Neuroscience, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Nov. 26, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common stock, par value $0.0001 per share <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">8,454,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">13.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 110,415,952.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 15,248.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text"> 1. The amount of shares registered represents an aggregate of 8,454,514 shares of Alto Neuroscience, Inc. common stock, par value $0.0001 per share ("common stock"), which includes 4,622,251 shares of common stock that may be issued upon the exercise of pre-funded warrants, held by the selling stockholders named in the prospectus that forms a part of this registration statement (this "Registration Statement"). Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional number of shares of common stock as may be issuable as a result of stock splits, stock dividends, or other distribution, recapitalization or similar events with respect to the shares of common stock being registered pursuant to this Registration Statement. The proposed maximum offering price per share has been estimated in accordance with Rule 457(c) under the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per unit and the maximum aggregate offering price are based on the average of the high and low sale price of common stock, as reported on the New York Stock Exchange on November 24, 2025, which date is within five business days prior to filing this Registration Statement.
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Nov. 26, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 110,415,952.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">15,248.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 15,248.44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2531771d1_ex-filingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tm2531771d1_ex-filingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tm2531771d1_ex-filingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="tm2531771d1_ex-filingfees.htm">tm2531771d1_ex-filingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2531771d1_ex-filingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "tm2531771d1_ex-filingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2025": 2,
    "http://xbrl.sec.gov/ffd/2025": 6
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 22,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2531771d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2531771d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2531771d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2531771d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-25-116507-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-116507-xbrl.zip
M4$L#!!0    (  ".>EM686L,)@T  -IE   =    =&TR-3,Q-S<Q9#%?97@M
M9FEL:6YG9F5E<RYH=&WM'6MSVS;R<_(K<&QS26;THAY^R+8ZJF/?>9JJGMB=
MZ7VZH4A(PH0B>0!H2?WUMPN2XD.D7J8<IU7S1286^][% L2RES_-IS9YHEPP
MU[EZK]<:[PEU3-=BSOCJ??_A^N[N_4^]MY<3"6  ZH@K;2*EUZW79[-9;=:J
MN7Q<U\_/S^MSA-$"H.[<9L[78E <78(.N<U2H/A$ 3<;C5:=.4(:CDF3\%8\
M(0E\4@\&(U FW'93/UV'/(!83I@7P>K("+!-__CYR^<87.;#QZ!UR0U'C%P^
M-22H&#%UJHUFM7F20%(5U$PA@K]K8_=I(YZS:DN/\*QH/"TI#@\-$:M1L#S[
M *Q>_^/7SP_FA$Z-:E;Y%LUH/N(4!F!NLQ,!CD96/B ,!("]MX1<3JAAX0_X
M*9FT:>_FC^KMW>>[P;_([<W-PV4]>(J@]0CV<NA:BW"2Q9Z(D N;7FD6$YYM
M++K$<1VJ!>, P>9=G$AY]"1\QBR+.O&SX"E,'?A3RIE)'&,*2(';[BTH_='3
MB.DZDL[E%SJZTKBI$082LOE3M04VZ#U46Y?U%(:M<#_XPRD3PEF/O[DW_EM*
M;^83-F1R/866MJ+YW8B!_;LW#EAK<4T=\%7[SK'H_!>Z6$>UK?4:X&^0$MIG
MC?TI?J%C)C ^Y !&UA$$K^O;TB4#ZG-7F Q2':V0.\>L[:/<WT8C>.*,'XVA
M30=&/N' T;BY @P!V'68?:5)[H._[LF H');\@G0WJ#>WX?@M3L=0D*R[D%[
M'C6E+[8B7CQM+2-J(!NHR!NGH$NTG4AQC2FN*U3B C:(6F6Z$XX<82821:D(
M?U3Q1VTN+"V<)Q<>""W8U+.I5L\PE<= P)AP?9[E2ZUPW5!!2C&@H"3$$H8J
M?TX/+0>9A<,C1CE10M+<)>/Z[I=T5&4G9PC7BRF'=#VPBFL5, 7+ Y>?#$E[
MJ,"JKL/*%N&,Q_+G4L<JF!F-Y+*ZRD\T$JIX@_+=T8C;_]5?BP5B5=+Q%$"R
MH^&XQ91+6K_2Z1#H6PQ@5=&62D7].1/:*@9<*2%=8C$Q<'OZ93WQURJY^BJ]
M%9;K:WC^F_B4[[# H7Y_^)3O3%-J")_37EAE=@$P0AL-Y5!$O.O(>3!O/;U0
M)OA9 KF'B0%I;1N"0D'N3#+,J)G,&23_1.4&3LN>XK)O"2=Q*8F*P!FSY*1+
MSL_?79 16*XZ,J;,AJ*PSYEA5\B_J?U$)3.-"A%03T/AS=DH!!7L3]HES88G
M+PB:O&K8;.QTB0E^3/E%0@.7,A40E]*"Y<\6G@'1V-8B7CS#PFU4=>A*Z4Z[
MI-:ATZP:O14W'O:N#=OT;57F$W=$;AD$ZIA )4?4J@D*'F:=V$MK65I)[2:9
MS>&\B-OFENRNYH^]"^F3UJ9"-Y#H.Y1_CVKUI+U/M?H\#<%O]+'<B"O2%$3,
M/(Z.=#R.;->0RQ B87CJC<:[=(S9= 111](QMD2R5R#K)]Y<2QM[$F%\HASG
MVA'Y0)0\EF8NMZHS;G@ Q*GQM8H/LFXQ[*G()'H7;#6S%R2P,92(%C$<BUP;
MG"\(N/_,X!9YH*;/F60KD0S*G^S(<"Y[:3DX&T_D199E3%81<CQ^J+)Y-2BU
MNZ1HR]+[YP_GI^WVQ<"5I.]Y-C $ Y=UQ%4L1Z%[K?C*#F;>TJTB@"%HA7*
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M?\32^S]02P$"% ,4    "   CGI;5F%K#"8-  #:90  '0
M@ $     =&TR-3,Q-S<Q9#%?97@M9FEL:6YG9F5E<RYH=&U02P4&      $
, 0!+    80T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>tm2531771d1_ex-filingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <startDate>2025-11-26</startDate>
            <endDate>2025-11-26</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-26</startDate>
            <endDate>2025-11-26</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-331">S-3</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-332">S-3</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-333">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-334">0001999480</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-335">Alto Neuroscience, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="rc" id="ixv-363">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-364">Alto Neuroscience, Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-365">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-366">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-367">Common stock, par value $0.0001 per share </ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="offrl_1" id="ixv-368">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-369"
      unitRef="Shares">8454514</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-370"
      unitRef="USD">13.06</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-371"
      unitRef="USD">110415952.84</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-372"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-373"
      unitRef="USD">15248.44</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="INF" id="ixv-374" unitRef="USD">110415952.84</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="INF" id="ixv-375" unitRef="USD">15248.44</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="INF" id="ixv-376" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="INF" id="ixv-377" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="INF" id="ixv-378" unitRef="USD">15248.44</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-379"> 1. The amount of shares registered represents an aggregate of 8,454,514 shares of Alto Neuroscience, Inc. common stock, par value $0.0001 per share ("common stock"), which includes 4,622,251 shares of common stock that may be issued upon the exercise of pre-funded warrants, held by the selling stockholders named in the prospectus that forms a part of this registration statement (this "Registration Statement"). Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional number of shares of common stock as may be issuable as a result of stock splits, stock dividends, or other distribution, recapitalization or similar events with respect to the shares of common stock being registered pursuant to this Registration Statement. The proposed maximum offering price per share has been estimated in accordance with Rule 457(c) under the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per unit and the maximum aggregate offering price are based on the average of the high and low sale price of common stock, as reported on the New York Stock Exchange on November 24, 2025, which date is within five business days prior to filing this Registration Statement.
</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
